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Congenital heart disease (CHD) contributes to the rate of birth defects in the population with an 
incidence of nearly 1% of all live births (1).  CHD has significant Public Health importance due to its 
high incidence, clinical severity, and complexity of medical management.  In some cases, efficiently 
diagnosing the underlying cause of CHD is essential to providing optimal clinical care.  The etiology 
of CHD is hypothesized to be largely multifactorial in nature, but chromosome abnormalities account 
for 8-13% of all CHD (2, 3).  It has recently been recognized that submicroscopic chromosome 
abnormalities known as copy number variants (CNVs) may also play a role in causing CHD.  Array 
comparative genomic hybridization (array CGH) has recently been added as a first-tier test for 
neonates with CHD at our institution, due to its ability to detect CNVs which were previously 
undetectable by classical cytogenetic analysis.  Our study is a prospective chart review of data from 
neonates with CHD admitted to the Cardiac Intensive Care Unit at Children’s Hospital of Pittsburgh 
of UPMC.  The purpose of this study was to assess the clinical efficacy of array CGH as a first-tier 
test in this population.  Our results show that array CGH increases the detection rate of chromosome 
aberrations by 20% above classical cytogenetic analysis alone.  However, the majority of CNVs 
detected in our study had unclear clinical significance.  For this reason, collaboration between 
Cardiology and Medical Genetics is essential to interpreting the clinical relevance of array CGH 
results in order to provide an accurate, timely genetic diagnosis and ultimately improve the clinical 
care of neonates with CHD.                                                        
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Nomenclature 
I. Congenital heart defects  
a. AS: Aortic Stenosis 
b. ASD: Atrial Septal Defect 
c. AVSD: Atrioventricular Septal Defect  
d. BAV: Bicuspid Aortic Valve 
e. COA: Coarctation of the Aorta  
f. DORV: Double-outlet right ventricle 
g. D-TGA: D-transposition of the great arteries  
h. HLHS: Hypoplastic left heart syndrome  
i. IAA: Interrupted aortic arch     
j. LVOTO:  Left Ventricular Outflow Tract Obstruction  
k. PDA: Patent Ductus Arteriosus 
l. PFO: Patent Foramen Ovale 
m. PS: Pulmonary Stenosis  
n. RVOTO: Right Ventricular Outflow Tract Obstruction 
o. TOF: Tetralogy of Fallot 
p. VSD: Ventricular Septal Defect     
 
II. Other 
a.   Array CGH:  Array Comparative Genomic Hybridization  
b.   CNV: Copy Number Variant  
c.   DD/ID:  Developmental Delay/ Intellectual Disability  
d.   FISH:  Fluorescence In Situ Hybridization 
e.   MCA:  Multiple Congenital Anomalies 
f.  VUS:  Variant of Uncertain Significance       
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1.0  INTRODUCTION  
Congenital heart disease (CHD) encompasses any structural defect of the heart which is 
present at birth.  It contributes to the rate of birth defects in the population with an incidence of 
nearly 1% among all live births (1).  However, the incidence of moderate to severe CHD may be 
lower (3-6 in 1000 live births), while the true prevalence including of all types of CHD may 
approach 50 in 1000 live births (4-6).  The incidence is also higher among premature infants 
(2%, excluding PDA), stillborns (3-4%), and miscarriages (10-25%) (7).  There can be a wide 
range in the clinical severity of heart defects, but over half of all patients with CHD will receive 
a diagnosis within the first month of life (7).  In recent years there have been remarkable 
advances in surgical techniques for the treatment of CHD, which have the potential to 
dramatically increase life expectancy and quality of life.  Despite these advances, CHD is still 
the leading cause of mortality for children with birth defects (7), and its impact reaches into the 
fields of Medicine, Public Health, and Medical Genetics.                    
Despite many efforts to discover the etiology of CHD, the cause for the majority of cases 
of CHD is still unknown (8).  These gaps in knowledge regarding the developmental basis of 
CHD have limited scientific advances in diagnosis and treatment, and can make it challenging to 
provide an accurate estimate of recurrence risk.  Based on recurrence risks from epidemiologic 
studies, the majority of CHD is hypothesized to be multifactorial in origin, but several specific 
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causes have been identified.  These include environmental factors, such as maternal diseases and 
teratogenic exposures, as well as genetic factors, such as chromosomal abnormalities and single 
gene mutations.  In cases of CHD with a genetic basis, accurate and efficient diagnosis of the 
underlying genetic etiology is crucial to provide information about prognosis and involvement of 
other organ systems, as well as reproductive risks and testing options for other family members 
(4).                                                                        
It has been estimated that between 8 and 13% of all cases of CHD are associated with 
chromosomal abnormalities (2, 3), but this is likely to be an underestimate of the true prevalence 
due to the limitations of previous studies (9).  Some of these studies were large population-based 
studies, in which only a subset of individuals with CHD had genetic testing, often based on the 
presence of additional anomalies or organ system involvement suggestive of a genetic syndrome 
(2, 10).  Therefore, many individuals with CHD were unlikely to have received chromosome 
analysis, as only 25 to 40% of all patients with CHD are reported to have other birth anomalies 
(7, 11).  In addition, the detection of chromosome abnormalities was previously limited to 
aneuploidies or other large rearrangements detectable by classical cytogenetic analysis.  For the 
purposes of this study, classical cytogenetic analysis refers to a G-banded karyotype.  This 
method of chromosome analysis has been the gold standard for the detection of chromosome 
abnormalities, but its resolution is limited to imbalances greater than about 5 megabases (Mb) or 
larger (12).                
In recent years, various single gene mutations and submicroscopic chromosomal 
rearrangements have been discovered to play an important role in causing both syndromic and 
isolated CHD.  One well-studied example is 22q11.2 microdeletion syndrome (DiGeorge 
syndrome), which accounts for a significant portion (6%) of all cases of conotruncal heart 
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defects (13, 14).  However, there is still a substantial portion of CHD, both isolated and 
syndromic, for which the etiology is yet to be elucidated.         
With the evolution of array comparative genomic hybridization (array CGH), novel 
submicroscopic chromosome abnormalities have been recognized as another important cause of 
CHD.  Array CGH can detect these submicroscopic rearrangements, also known as copy number 
variants (CNVs), by analyzing the genome in high-resolution in comparison with a reference 
genome (15).  CNVs are often not detectable by classical cytogenetic analysis or targeted FISH 
studies.  Array CGH has been recently recommended as a first-tier test, in concert with classical 
cytogenetic analysis, for individuals with developmental delay/ intellectual disability (DD/ID), 
autism spectrum disorders (ASDs), and multiple congenital anomalies (MCA) (16), but the use 
of array CGH for individuals with CHD has not yet been studied extensively.  There have been 
several studies regarding the use of array CGH among individuals with CHD, but these have 
limited inclusion by age (fetuses, children, or adults) or by the presence or absence of other 
anomalies.  There has been little research to date regarding the use of array CGH in a cohort of 
live-born neonates, including those with apparently syndromic and apparently isolated CHD.  
Our study has been designed to fill this gap in prior research.                                    
At Children’s Hospital of Pittsburgh of UPMC, array CGH been added as a first-tier test 
for infants diagnosed with CHD in the Cardiac Intensive Care Unit.  However, there is still much 
to be learned regarding its clinical efficacy and detection rate in this population.  This study was 
designed to answer the following questions:  Does array CGH increase the detection rate of 
chromosome abnormalities among neonates with a congenital heart defect, in comparison with 
classical cytogenetic analysis alone?  Are there apparent relationships between type of CHD, 
syndromic features, and chromosome abnormalities among our study population?  Should array 
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CGH be used as a “first tier” test for a neonate with apparently isolated CHD or only in neonates 
with associated dysmorphic features or extracardiac abnormalities?  Thus, the quantitative aim of 
this study is to compare the detection rates of classical cytogenetic analysis and array CGH.  The 
qualitative aims of the study are to assess the clinical significance of all CNVs detected by array 
CGH, as well as to determine whether any relationship exists between type of CHD, extracardiac 
abnormalities, and chromosome abnormalities in our study population.                
Our study design is a prospective chart review.  Inclusion criteria for participation in the 
study included any neonate with a congenital heart defect and admitted to the Cardiac Intensive 
Care Unit (CICU) of Children’s Hospital of Pittsburgh of UPMC at less than four weeks of age.  
It is considered standard of care at our institution for any neonate with CHD to receive 
chromosome analysis and array CGH, as well as a physical exam by a geneticist to examine for 
dysmorphology.  After obtaining consent from the parents of the patient for study participation, 
data collected for our study included general medical history information, physical exam results, 
and genetic test results.  Statistical analysis of the data was performed using McNemar’s test as 
the primary outcome variable to analyze whether there is a significant difference between the 
detection rates of classical cytogenetic analysis and array CGH.          
The ultimate goal of this study is to provide data which may contribute to establishing 
guidelines for genetic testing of neonates with a CHD.  When applicable, the correct diagnosis of 
the genetic etiology of a congenital heart defect is critical to improving patient care by providing 
the family with genetic counseling information and providing the physician with guidance for 
medical management. The results of this study will be important to ascertain if the use of array 
CGH as a first-tier test for all neonates with CHD improves the efficiency and accuracy of 
diagnosis in this patient population.                                                   
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1.1 BACKGROUND   
1.1.1 Normal Cardiac Development   
The process of cardiac development is a complex and dynamic process.  In humans the 
process of cardiac development begins on days 15-16 of gestation and culminates on day 49 with 
the complete formation of the heart.  There are five main steps of cardiac development, including 
the following: (8):                           
1) Days 15-16: Precardiac cells migrate from the primitive streak to assemble the 
cardiac crescents, also known as the cardiogenic plates.   
2) Day 22: Formation of the primitive heart tube begins, as the cardiogenic plates fuse 
into one tube with two poles, the arterial pole and the venous pole.  The progenitor 
cells of the heart tube include inner endocardial cells and outer myocardial cells.      
3) Day 23: Cardiac looping begins as the primitive heart tube folds into a crescent shape 
to align future cardiac chambers.  Throughout this process, cells in specific sections 
of the heart tube become specialized and the segments begin to differentiate into 
primitive chambers and transitional zones, which come together at the inner curvature 
of the heart tube.  
4) Day 28:  Septation and heart chamber formation begins.  Formation of the septa 
occurs at the atrium, ventricle, and arterial pole.  The transitional zones, which will 
give rise to the septa, conduction system, fibrous heart skeleton, and valves, are 
incorporated in the primitive chambers which form the atria and ventricles.    
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5) Until Day 49:  During septation of the outflow tract, the neural crest cells enter the 
heart.  They are incorporated into the myocardium and begin the conduction system.  
The two endocardial cushions of the outflow tract fuse to form the outflow tract 
septum and the semilunar valve.  Cells from the lining of the myocardium migrate to 
form the coronary arterial tree.  By day 49, establishment of the cardiac conduction 
system and coronary vasculature is complete (8).         
There are four types of cardiac precursor cells which contribute to the developing heart 
(Figure 1).  The cells of the primitive heart tube are the first heart field, which will eventually 
form the left ventricle and atria, and contribute to all other structures of the heart except for the 
cardiac outflow tract.  The second heart field lies behind the heart tube; this will provide 
myocardial cells to contribute to the cardiac outflow tract, part of the atria, and right ventricle.  
The cardiac neural crest cells give rise to the aortopulmonary septum and great vessels.  Cells of 
the proepicardium will form the epicardium and coronary vessels (17).         
 
Figure 1.  Precursor cells and their contribution to the four-chambered heart (17) 
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1.1.2 Congenital Heart Defects 
Due to the complexity of the process of normal cardiac development, there are a variety 
of mechanisms which may contribute to defective cardiac structure or function.  These include 
mechanical, cellular, and molecular factors.  On a cellular level, the processes of growth, 
differentiation, and apoptosis are the basis for the entire course of cardiac development.  
Disruptions of these cellular processes at specific points in cardiac development have been 
documented to cause defects in cardiac looping, septation, chamber formation, and arch 
regression in animal models (8).  On a molecular level, there are a variety of cardiac specific 
transcription factors which are integral to the regulation of heart development.  They initiate 
heart development, determine cardiac cell fates, control expression of contractile proteins, and 
control the morphological development of heart structures (17).  Mutations in the genes encoding 
these transcription factors have the potential to cause defective cardiac development.   
Three of the most important transcription factors identified to date which are involved in 
heart development include NKX2.5, GATA4, and TBX5.  WNT and BMP provide the first signals 
to initiate cardiac development; these signals target NKX2.5.  NKX2.5 is a homeobox gene which 
is expressed in cardiac progenitor cells and involved in the development of the heart tube and left 
ventricle, which originate from the first heart field.  GATA transcription factors regulate cardiac 
contractile proteins and other regulatory genes, including NKX2.5, MEF2, and HAND.  MEF2 is 
involved in the differentiation of types of muscles in the heart, activating certain contractile 
proteins, and the development of structures from the second heart field.  HAND genes regulate 
growth of the ventricles.  TBX genes control cardiac fate, differentiation and the development of 
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the dorsal vessel, and have been associated with the development of the atria, ventricles, and the 
cardiac conduction system (17).         
Even though a heart defects may originate with a single defective step of cardiac 
development, cardiac defects often evolve in a progressive manner throughout gestation, even 
after the completion of heart development at day 49.  For example, hypoplastic left heart 
syndrome (HLHS) is thought to originate with changes in cardiac anatomy which alter the 
function of left ventricular inflow or outflow, but progression of the heart defect into the 
complete entity of HLHS occurs throughout gestation (8).                                                                
Although there have been many advances in our understanding of the molecular and 
developmental mechanisms which result in CHD, our understanding is not yet sufficient to 
classify types of CHD based on their developmental origin.  Therefore, CHD can be categorized 
on the basis of clinical features, such as cyanotic versus non-cyanotic defects, or the anatomical 
segment of the heart that is affected.  CHD may also be classified on the basis of complexity, as 
each individual with CHD may have only one isolated defect or a combination of multiple 
defects.  A classification strategy developed by Botto et al., based on cardiac anatomy, was 
utilized to categorize types of CHD for the purposes of this study.  Cardiac phenotypes are 
categorized into Level 1, 2, and 3 groups, from detailed to broad categories, respectively (18).  
Broad categories of CHD (Level 3 groups) are listed as the section headings below, which are 
further subdivided into Level 2 groups.  Although the etiology of all types of CHD is largely 
unknown, most have been associated with various genetic syndromes.  A description of each 
type of CHD and the most common associated genetic syndromes are provided below, but the 
genetic causes are discussed in greater detail in Section 1.1.3.2.  A diagram of normal heart 
anatomy is provided below for comparison with each description of defective heart structure.                                                                                                                      
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Figure 2.  Normal heart anatomy (19)  
1.1.2.1 Outflow tract defects    
Outflow tract defects limit the either the flow of oxygen-rich blood through the aorta or oxygen-
poor blood through the pulmonary artery, which can result in hypertension or ventricular 
hypertrophy.  Right ventricle outflow tract obstruction defects (RVOTO), which are obstructions 
of the pulmonary outflow tract, include the following:                        
• Pulmonary atresia (PA):  Absence of the pulmonary valve; when the ventricular septum 
is intact, a patent ductus arteriosus provides the only pulmonary blood flow (20).          
When associated with a ventricular septal defect, it is a variant form of tetralogy of 
Fallot.   
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• Ebstein’s anomaly:  Downward displacement of an abnormally structured tricuspid valve 
into the right ventricle, which it is often associated with functional pulmonary stenosis or 
atresia (20).  The majority of cases are sporadic, but it can be associated with maternal 
lithium exposure during the first trimester (4, 21).                    
• Pulmonary valve stenosis (PS):  Narrowing of the pulmonary valve which restricts blood 
flow from the right ventricle to the pulmonary artery.  PS accounts for 7-10% of all CHD 
(20), and is very common among patients with Noonan syndrome, Alagille syndrome, 
and a variety of other genetic syndromes and chromosome abnormalities (4).  In 
approximately 50% of cases of PS due to valve dysplasia, a mutation in PTPN11, 
associated with Noonan syndrome, is detected (20).    
o Peripheral pulmonary stenosis is a distinct entity caused by constrictions of the 
pulmonary artery; this can be associated with both Williams and Alagille 
syndromes (20).                  
• Tricuspid atresia:  Absence of the tricuspid valve between the right atrium and right 
ventricle, causing the systemic venous return to enter the left heart through a patent 
foramen ovale or ASD (20).  The majority of cases are sporadic (4).         
Left ventricle outflow tract obstruction defects (LVOTO) are obstructions of the aortic outflow 
tract which include the following:      
• Aortic valve stenosis (AS):  Narrowing of the aortic valve between the left ventricle and 
the aorta; this is frequently associated with other types of CHD including mitral stenosis 
and coarctation of the aorta (20).  It can be associated with a variety of chromosome 
abnormalities, Noonan syndrome, and Turner syndrome (4).        
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• Aortic atresia:  Absence of the aortic valve which connects the left ventricle and the aorta 
(20). This defect has been associated with 11q deletion, Turner syndrome, Trisomies 13 
and 18, and 4p deletion (4).       
• Supravalvular aortic stenosis (SVAS):  Narrowing of the aorta, commonly associated 
with Williams-Beuren syndrome (4).    
• Interrupted aortic arch type A (IAA, A):  Blockage between the ascending and 
descending aorta, just beyond the branch leading to the subclavian artery; this defect 
results from abnormal aortic arch development, between weeks 5 and 7 of gestation (22).    
• Coarctation of the aorta (COA):  Narrowing of the aorta which primarily occur at the 
origin of the ductus arteriosus (20).  This defect is frequently seen in Turner syndrome, 
but has also been associated with other chromosome abnormalities (4).  When associated 
with mitral valve abnormalities and AS, it is referred to as the Shone complex (20).     
• Hypoplastic left heart syndrome (HLHS):  This is a group of related defects, including 
underdevelopment of the left heart (left ventricle, aortic valve, and mitral valve) and of 
the ascending aorta (20).  For blood to flow into the aorta, it must flow through an atrial 
septal defect into the pulmonary artery, and then through a patent ductus arteriosus.  
HLHS can be associated with various chromosome abnormalities, such as 11q deletion, 
Turner syndrome, Trisomy 13 and 18, and 4p deletion; and also in familial aggregation of 
left-sided obstructive heart defects (4). 
• Bicuspid aortic valve (BAV):  Aortic valves are typically tricuspid in structure, but up to 
2% of the general population have a bicuspid aortic valve (7).  Because of its high 
prevalence, BAV will not be reported in this study.                                   
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1.1.2.2 Septal defects       
Septal defects are openings in the septum dividing the left and right atria or ventricles, allowing 
the oxygen-rich blood in the left heart to mix with oxygen-poor blood in the right heart.  These 
defects may be associated with left outflow tract obstruction defects, such as coarctation of the 
aorta or aortic stenosis (4, 18).  Septal defects include the following:              
• Ventricular septal defects (VSD):  A VSD is an opening in the septum between the 
ventricles, which allows oxygen-rich blood to flow into the right ventricle.  VSDs are the 
most common type of CHD, accounting for 30-35% of all major heart defects.  VSDs 
may be further categorized depending on their location in the ventricular septum; 
membranous VSDs are most common (20).  VSDs are a common finding in Holt-Oram 
syndrome, familial ASD, and various other genetic syndromes (4).                     
• Atrial septal defects (ASD):  An ASD is an opening between the atria which allows 
oxygen-rich blood to flow into the right atrium instead of the left ventricle.  ASDs, along 
with PDA, are the second most common type of heart defect, accounting for 6 to 8% of 
all heart defects (20).  Depending on location in the atrial septum, ASDs may be further 
defined as secundum type, sinus venosus, or coronary sinus (18).  The majority of ASDs 
are sporadic, but may be associated with Holt-Oram syndrome, familial ASD, Ellis-van 
Creveld syndrome, and various other genetic syndromes (20).               
1.1.2.3 Atrioventricular Septal Defects 
Atrioventricular septal defects (AVSDs) are also referred to as endocardial cushion defects, 
because the endocardial cushions are the developmental precursors of the septum and the mitral 
and tricuspid valves (23).  AVSDs typically includes contiguous atrial and ventricular septal 
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defects along with abnormalities of the atrioventricular valves (mitral and tricuspid) (20).  
Approximately 60% of infants with AVSD have Down syndrome, but AVSDs may also be 
associated with other chromosome abnormalities (mainly deletion 8p and deletion 3p) and 
various monogenic syndromes (4, 24).  Types of AVSDs include:              
• Complete atrioventricular septal defects (AVSD): An AVSD is a large opening in the 
center of the heart which allows blood flow between all four heart chambers; this is 
associated with one common atrioventricular valve in place of the mitral and tricuspid 
valves.  This is the most common form of AVSD among individuals with Down 
syndrome (20).                         
• Transitional AVSD:  Transitional AVSDs involve only the atrial or ventricular portion of 
an AVSD; there are often two separate atrioventricular valves (20, 24):      
o Inlet-type VSD:  The isolated ventricular component of an AVSD, which is an 
opening in the posterior ventricular septum beneath the tricuspid valve (20)       
o Primum type ASD:  The isolated atrial component of an AVSD, which is an 
opening in the region of the mitral and tricuspid valves (20).   
1.1.2.4 Conotruncal heart defects 
Conotruncal defects arise from abnormal development during septation of the aortic and 
pulmonary outflow tract (14).  As a group, conotruncal defects account for a large portion (25-
30%) of all apparently isolated CHD (25).    DiGeorge syndrome has been identified as a cause 
for a significant portion (6%) of all cases of conotruncal defects (13), but other chromosome 
abnormalities have been associated with this type of CHD as well (4).  Conotruncal defects 
include:                           
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• Tetralogy of Fallot (TOF):  A combination of heart defects including a VSD, pulmonary 
stenosis, an aorta that overrides the ventricular septum, and hypertrophy of the right 
ventricle (20).  TOF can be associated with various genetic syndromes, mainly  including 
DiGeorge syndrome, Alagille syndrome, and Cat-eye syndrome (22pter→q11 
duplication) (4).                            
• Double outlet right ventricle (DORV):  A defect in which both the pulmonary artery and 
aorta stem from the left ventricle.  This can be associated with additional defects; for 
example, Taussig-Bing malformation includes DORV, SVD, aortic stenosis, and possibly 
COA (20).  DORV has been associated with various chromosome abnormalities and 
trisomies, but rarely is associated with DiGeorge syndrome (4).          
• Persistent truncus arteriosus:  The pulmonary artery and aorta are replaced by a single 
blood vessel (truncus arteriosus) which stems from the right and left ventricles; this must 
be associated with a VSD (20).          
• Interruption of the aortic arch (IAA, types B and C):  IAA, Type B is a blockage between 
the left carotid artery and left subclavian artery; it is the most common type of interrupted 
aortic arch defects.  IAA type C is a blockage between the innominate artery and left 
carotid artery (22).  Both IAA and truncus arteriosus have been associated with DiGeorge 
syndrome, Trisomy 8, and deletion 10p (4).                 
• Conoventricular VSD:  An opening at the location where two portions of the ventricular 
septum meet below the pulmonary and aortic valves (26).    
• Transposition of the great arteries (D-TGA):  An inversion of the pulmonary artery and 
aorta, resulting in the aorta originating from the right ventricle and the pulmonary artery 
originating from the left ventricle, while the systemic and pulmonary veins return 
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normally (20); it may or may not be associated with a ventricular septal defect.  It has 
been associated with various chromosome abnormalities, Trisomy 21, and Trisomy 18, 
but rarely is associated with DiGeorge syndrome (4).        
1.1.2.5 Anomalous-Pulmonary Venous Return 
Anomalous-Pulmonary Venous Return (APVR) defects cause drainage of one or more 
pulmonary veins into the systemic circulation system (20).  APVR defects may be isolated or 
associated with outflow tract obstruction defects (18).  Types of APVR include:       
• Total anomalous-pulmonary venous return (TAPVR):  All of the pulmonary veins drain 
into the right atrium instead of the left atrium, allowing all oxygenated and deoxygenated 
blood to mix; the presence of an ASD of PFO is necessary to maintain any systemic 
blood flow (20).  The majority of cases are sporadic(4).               
• Partial anomalous-pulmonary venous return (PAPVR):  One or several pulmonary veins 
drain into the right atrium instead of the left atrium; this is frequently but not always 
associated with an ASD (20).             
1.1.2.6 Patent Ductus Arteriosus  
Patent Ductus Arteriosus (PDA) is an opening between the pulmonary artery and aorta which 
fails to close properly at birth, resulting in shunting of blood from the aorta to the pulmonary 
artery.  This can increase strain on the heart and result in pulmonary hypertension, depending on 
the size of the PDA (20).  Because the ductus arteriosus closes at birth, PDA is a very common 
finding among premature infants and it accounts for 6-8% of all heart defects (7).  It is also 
present in 10% of patients with other types of CHD as is sometimes necessary to maintain 
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viability (20).  For this reason, PDA will not be reported in our study if it is combined with other 
structural defects.                       
1.1.2.7 Laterality defects 
Laterality defects have not been associated with any well-defined genetic syndromes, but have 
been reported in patients with chromosome abnormalities.  This category can be subdivided into 
the following (4):     
• Heterotaxy:  Abnormal placement of organs, including the heart, on the opposite side of 
the body.  This may be isolated or associated with other defects in cardiac structure, 
including ASD, VSD, AVSD, ventricular hypoplasia, pulmonary stenosis or atresia, or 
APVR defects (18, 20).              
o Asplenia:  Both atria have the structure of the right atrium; this is also referred to 
as right atrial isomerism; this is associated with a central liver, absent spleen, and 
two structurally right lungs (20).    
o Polysplenia: Both atria have the structure of the left atrium; this is also referred to 
as left atrial isomerism; this condition is associated with several small spleens, 
absence of part of the vena cave, and two structurally left lungs (20).      
1.1.2.8 Complex and Single Ventricle Defects 
The following types of heart defects are included in this category:        
• Complex cardiac malformations:  A combination of heart defects including three or more 
defects (excluding simple ASD or VSD) (18).      
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• Single ventricle heart defects (SV):  Single ventricle defects include double inlet left 
ventricle (DILV), in which only the left ventricle is developed, and double inlet right 
ventricle (DIRV), in which only the right ventricle is developed(18); both allow total 
mixing of systemic and pulmonary blood flow.  These may be associated with 
transposition of the great arteries (20).    
• L-transposition of the great arteries (L-TGA):  Transposition of the aorta and pulmonary 
artery, as well as reversal of the right and left ventricle, resulting in the complete reversal 
of normal blood flow.  When isolated, this defect has a better prognosis than D-TGA, 
however it is often associated with additional defects (18, 20).                        
1.1.3 Etiology and Recurrence of CHD           
Based on early epidemiologic studies, approximately one quarter of CHD has an 
identifiable chromosomal or environmental cause, but the majority of cases of CHD have no 
identifiable cause.  Among CHD with no identifiable cause, the minority of cases are associated 
with extracardiac features (syndromic CHD) but the majority of cases have no apparent 
extracardiac manifestations (isolated CHD).  In cases in which the etiology is unknown, it may 
be difficult to determine the accurate recurrence risk.  Based on early epidemiologic studies, the 
general recurrence risk for CHD has been estimated as 2 to 5% (27).           
Various studies have attempted to characterize recurrence risk estimates for specific types 
of CHD.  In a recent study based on the Danish national population and health registers, the 
relative risk for a first degree relative to have the same type of CHD was in the range of 2- to 6-
fold, depending on the type of CHD (RR= 1.8- 5.2), while the relative risk for a first degree 
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relative to have a discordant type of CHD was still nearly 3-fold (RR= 2.68) (21).  In a 
continuation of this study, it was hypothesized that shared gene mutations or epigenetic factors 
might increase susceptibility for all types of CHD which originate from the same embryologic 
segment.  This could cause an increased relative risk for specific pairings of CHD within a 
family.  However, results of this study showed that all combinations of discordant CHDs had 
very similar relative risks, in the range of 2- to 4- fold (22).                     
These data regarding recurrence risk have led to various hypotheses regarding genetic 
mechanisms which could contribute to CHD with an unidentified cause.  Modes of inheritance 
which are consistent with a recurrence risk in the range of 2 to 5% include multifactorial 
inheritance or polygenic inheritance (8, 27).  Multifactorial inheritance describes traits caused by 
complex interactions between many genes and environmental factors.  Polygenic inheritance 
describes traits caused by interactions between multiple genes.  The aggregation of dissimilar 
types of CHD in the same family could be attributed to pleiotropy, defined as multiple 
phenotypic effects caused by variation in the same gene (28).  The similarity in recurrence risk 
between all combinations of discordant CHD would be consistent with various genetic 
mechanisms, including syndromes associated with multiple types of CHD, allelic variants within 
the same gene which cause distinct types of CHD, and shared environmental factors which can 
impact different stages of cardiac development and lead to different types of CHD (29).                                       
According to the hypotheses detailed above, it is generally thought that many cases of 
CHD without an identifiable cause result from the combination of multiple genetic alterations 
which increase susceptibility to CHD along with the interaction of environmental risk factors (4).  
However, it has recently been suggested that the relatively low recurrence risks would also be 
consistent with a high de novo rate of pathogenic mutations or submicroscopic chromosome 
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abnormalities (30).  In addition, the similar risks for concordant and discordant CHD within the 
same family could also be consistent with reduced penetrance and variable expressivity, which 
are characteristic of submicroscopic chromosome abnormalities.  These genomic imbalances are 
recently being studied in the context of CHD and may prove to be an important contributor to the 
etiology of CHD with an unidentified cause.                                                                                                                                                                                                                                            
1.1.3.1 Environmental Factors    
The most common environmental factors which can affect cardiac development and 
cause CHD include maternal disease and teratogenic exposures during pregnancy.  Maternal 
diseases which increase risk for CHD include rubella infection, phenylketonuria, and diabetes.  
For example, pre-gestational diabetes causes a relative risk in the range of 3-7 (29), which may 
be slightly higher than relative risk of having a first degree relative with CHD.  Maternal 
teratogenic exposures which increase risk for CHD include retinoic acid, lithium, antiepileptic 
drugs including valproic acid and phenytoin, and alcohol (20, 30).  Paternal exposures may also 
play a role, as pre-conception paternal occupational exposure to chemicals has recently been 
associated with increased risk for CHD in the fetus (31).                                   
1.1.3.2 Genetic Factors     
There are many genetic factors which have been associated with congenital heart defects, 
including single-gene defects, large chromosome abnormalities, and submicroscopic 
chromosome abnormalities.  Single gene mutations have been associated with both isolated CHD 
and syndromic CHD, while large chromosome abnormalities are generally associated with 
syndromic CHD.  Submicroscopic chromosome abnormalities have been implicated as a cause 
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for both isolated and syndromic CHD, although the reported prevalence and clinical significance 
of submicroscopic chromosome abnormalities among patients with CHD have been variable.                    
Many single genes associated with CHD have been discovered thus far, but it is thought 
to be unlikely that single gene defects account for the majority of isolated CHD, as the majority 
are likely to be due to multifactorial inheritance (4).  Mutations in single genes which have been 
reported as a cause of isolated CHD include NKX2.5, CFC1, PROSIT240, ZFPM2/FOG2, 
CRELD1, TUPLE1, GATA4, ZIC3, ACVR2B, LEFTY1, and NOTCH1 (4, 8).  Several of these 
genes encode cardiac specific transcription factors which are described in detail in Section 1.1.2.          
Three of the most well-known monogenic syndromes associated with CHD include Holt-
Oram syndrome, Noonan syndrome, and Alagille syndrome.  The majority of patients diagnosed 
with Holt-Oram syndrome carry heterozygous mutations in TBX5, a key transcription factor that 
regulates gene expression during embryogenesis.  Classic cardiac features of Holt-Oram are 
found in seventy-five percent of patients and include specific congenital heart defects (ASD 
and/or VSD) or progressive AV cardiac conduction disease.  Holt-Oram syndrome is also 
characterized by upper-limb radial ray malformations (4, 8, 32).  Noonan syndrome is 
characterized by short stature, characteristic facies, webbed neck, developmental delay (DD), 
and chest deformities among other features.  Eighty to ninety percent of patients with Noonan 
syndrome have CHD; the most common cardiac features include hypertrophic cardiomyopathy, 
PS, COA, ASD, VSD, AVSD, and TOF (4, 33).  Noonan syndrome is genetically heterogeneous; 
the majority of Noonan syndrome is caused by heterozygous mutations in PTPN11, KRS, or 
SOS1 but other genes may exist which have not yet been discovered (4).  Similarly, Alagille 
syndrome is most often caused by a heterozygous mutation in JAG1 or NOTCH2, but can also be 
caused by a microdeletion of 20p12.  The most common types of CHD associated with Alagille 
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syndrome are peripheral pulmonary artery stenosis, ASD, VSD, TOF, and COA (34).  Other 
characteristic clinical features of Alagille syndrome are cholestasis, congenital heart defects, 
posterior embryotoxon in the eye, characteristic facies, and butterfly vertebrae (35).             
Other single gene disorders associated with congenital heart defects include Char 
syndrome (TFAP2B), CHARGE association (CHD7), Ellis-van Crevald syndrome (EVC, EVC2), 
Marfan syndrome (FBN1), Marfan-like syndrome (TFGBR2), Cardiofaciocutaneous syndrome 
(KRAS, BRAF, MEK1, and MEK2), and Costello syndrome (HRAS).  In addition, DiGeorge 
syndrome, is most often caused by a microdeletion of 22q11.2, may also be caused by mutations 
in TBX1 which is located in the 22q11.2 region.  The most common types of CHD associated 
with DiGeorge syndrome include conotruncal defects (TOF and truncus arteriosus), IAA, and 
VSD.  Classic extracardiac features of DiGeorge syndrome include palate abnormalities, immune 
deficits, hypocalcaemia, and learning difficulties (8, 36).                       
Large chromosome abnormalities are another well-documented cause of syndromic 
congenital heart defects.  Classical cytogenetic analysis has been clinically available since the 
development of high resolution banding methods in the 1970s (37).  This type of chromosome 
analysis uses a G-banded karyotype to visualize chromosomes at metaphase in order to identify 
aneuploidies and large chromosomal aberrations or rearrangements.  The estimate that 
chromosome abnormalities account for 8 to 13% of all CHD originated from early epidemiology 
studies from the late 1980s (3, 38).  However, these studies have several limitations.  They took 
place before the development of more advanced technologies for chromosome analysis, so the 
only chromosome abnormalities included were aneuploidies and large chromosomal 
rearrangements detectable by classical cytogenetic analysis (10).  In addition, chromosomal 
analysis was often ordered only when extracardiac abnormalities indicative of a genetic 
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syndrome were present, so patients with apparently isolated CHD would likely not have received 
chromosome analysis.                                            
 The most common aneuploidies associated with congenital heart disease include Trisomy 
21 (Down syndrome), Trisomy 18, Trisomy 13, 45,X (Turner syndrome), and 47,XXY 
(Klinefelter syndrome).  Down syndrome is the most common chromosomal aneuploidy in the 
general population; among individuals with Down syndrome, the prevalence of heart disease is 
between 40 to 50%.  In this population, AVSDs account for the majority of heart defects, but the 
remainder include VSD, ASD, TOF, and D-TGA.  Trisomies 13 and 18 have a much lower 
incidence in the general population, but are associated with a much higher prevalence of CHD.  
Approximately 80% of infants with Trisomy 13 and 90-100% of infants with Trisomy 18 have 
CHD.  Among individuals with Turner syndrome, 25-35% have CHD, including COA, BAV, 
valvar aortic stenosis, HLHS, and aortic dissection.  Among individuals with Klinefelter 
syndrome, approximately 50% have CHD, including mitral valve prolapse, PDA, and ASD (4).  
Large chromosome abnormalities associated with CHD include Cri-du-chat syndrome (deletion 
5p, critical region at 5p15), Wolf-Hirschhorn syndrome (deletion 4p, critical region at 4p16.3), 
deletion 8p syndrome (ranging from 8p218pter), deletion 10p (ranging from 10p1310pter), 
and Jacobsen syndrome (deletion 11q23).  The prevalence of congenital heart defects among 
individuals with these large chromosome abnormalities is high, often in the range of 30 to 75% 
of all individuals affected (4).  For example, the prevalence of CHD among individuals with Cri-
du-chat syndrome is approximately 30-60%, which primarily includes PDA, VSD, ASD, and 
TOF (4).                                
Fluorescence in situ hybridization (FISH) is a more recent technology which became 
clinically available in the late 1980s.  The purpose of targeted FISH is to identify submicroscopic 
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chromosome abnormalities associated with microdeletion or microduplication syndromes; these 
chromosome abnormalities are often too small to be visualized by classical cytogenetic analysis.  
FISH uses fluorescent probes, with both test and control sequences, which hybridize to 
metaphase chromosomes.  After hybridization, fluorescence microscopy is used to visualize the 
number of probes which have hybridized to the region of interest.  In targeted FISH analysis, the 
presence of only one copy of the test probe indicates a deletion of the region of interest, two 
copies of the test probe indicate a normal sequence, and three copies of the test probe indicate a 
duplication.             
Subtelomere FISH is a specialized form of FISH which can identify chromosome 
abnormalities in the gene-rich subtelomeric regions.  These regions contain unique chromosome-
specific sequences.  Among individuals with clinical indications including multiple congenital 
anomalies (MCA), developmental delay/ intellectual disability (DD/ID), dysmorphic facies, and 
other specific congenital anomalies, the prevalence of subtelomeric chromosome abnormalities 
has been reported as 4 to 9%.  Subtelomeric rearrangements have also been reported in children 
with congenital heart defects, including aortic arch abnormalities, VSD, ASD, MVI, and PS with 
VSD (39, 40).  Due to such evidence, Schellberg et al. concluded that subtelomeric FISH has 
significant clinical utility as a diagnostic tool for individuals with MCA with mental retardation 
and/or CHD and an apparently normal karyotype (41).                                           
Some of the most common submicroscopic rearrangements associated with CHD include 
Williams-Beuren syndrome (microdeletion 7q11.23), Smith-Magenis syndrome (microdeletion 
17p11.2), and DiGeorge syndrome (microdeletion 22q11.2).  Although these syndromes have a 
relatively low prevalence in the general population, the prevalence of CHD within these 
syndromes is very high.  For example, approximately 53 to 85% of patients with Williams-
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Beuren syndrome and 75% of patients with DiGeorge syndrome have a congenital heart defect 
(4).  The association between DiGeorge syndrome and CHD has been well-studied.  Among 
patients with DiGeorge syndrome, conotruncal defects including TOF, TOF with pulmonary 
atresia, truncus arteriosus, and IAA, are the most common type of CHD.  However, almost all 
types of CHD have been reported in patients with DiGeorge syndrome; this exemplifies the 
phenotypic variability which is characteristic of submicroscopic genomic imbalance syndromes.  
The developmental basis of the CHD in DiGeorge syndrome has been associated with the 
haploinsufficiency of the genes TBX1, CRKL, and ERK2, which causes dysfunction of neural 
crest cells and the anterior heart field (42).                                                                 
Targeted FISH can be used to test for any of these syndromes, but it is generally reserved 
for patients with clinical features which are indicative a specific genetic syndrome.  Among 
neonates, this can present a challenge, as extracardiac features may be subtle or not yet apparent.  
Because of the high prevalence of CHD among patients with DiGeorge syndrome and the 
difficulty of recognizing additional features, FISH has been utilized by some as a first-tier test 
for neonates with CHD.  Baker et al. analyzed the detection rate of FISH for 22q11.2 among 110 
neonates and infants with CHD admitted to the Cardiac Intensive Care Unit at Children’s 
Hospital of Pittsburgh.  In this population, the addition of FISH for 22q11.2 did increase the 
number of diagnoses by 5% above the 14% detection rate of chromosome abnormalities by 
classical cytogenetic analysis alone, to yield a total detection rate of 19% (43).                            
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1.1.4 Chromosomal Microarray Analysis and Copy Number Variants      
A novel technology which is now widely used as a clinical diagnostic tool is 
chromosomal microarray (CMA).  CMA is the equivalent of hundreds to thousands of FISH tests 
for microdeletions and microduplications (44); it detects submicroscopic chromosome 
abnormalities, also known as copy number variants (CNVs), across the entire genome at a high 
resolution.  By definition, CNVs are any DNA segment greater than 1 kb in length with which 
have variable copy number in comparison with a reference genome (45).  CNVs can occur 
anywhere in the genome, although they are most frequent in regions flanked by low copy repeats 
(LCRs), which are sequences with 98-99% sequence identity (44).  They are most often too 
small to be detected by classical cytogenetic analysis.  They may be benign or pathogenic, due to 
abnormal dosage or dysregulation of one or more genes in the region of loss or gain (44).          
The term CMA includes microarray-based comparative genomic hybridization (array 
CGH) and single nucleotide polymorphism (SNP) arrays; array CGH is the type of chromosomal 
microarray utilized in our study.  This test can be performed by using cloned bacterial artificial 
chromosomes (BACs) or synthesized DNA fragments (oligos).  These fragments are designed to 
match specific loci across the entire genome and are fixed to a glass surface.  Patient and control 
DNA is labeled and then allowed to hybridize to the DNA fragments on the glass microarray 
chip.  The intensity of the hybridization patterns is analyzed to detect any variation copy number 
between patient and control DNA.                     
Over time, the coverage and resolution of array platforms has evolved.  Targeted BAC 
arrays were the first to be developed.  These included hundreds of BAC clones which were 
targeted to specific regions in the genome with known clinical significance, such as 
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microdeletion syndrome regions, subtelomeric regions, and pericentromeric regions.  Targeted 
arrays simultaneously test regions with known clinical significance.  Their interpretation is 
uncomplicated, but they are not able to detect potentially pathogenic CNVs which are located in 
regions without probe coverage.  Whole genome arrays were developed next, with BAC clones 
covering the backbone of the entire genome.  Oligonucleotide arrays are the most recent form of 
whole genome arrays, which have a higher density of probe coverage across the genome.  
Current oligonucleotide arrays generally have a resolution of 20-50 kb in targeted regions of the 
genome and 100-250 kb in backbone regions.  The majority have a minimum resolution of at 
least 400 kb across the genome (16).  Overall, the resolution of array CGH is at least five- to ten-
fold greater than classical cytogenetic analysis, which is generally limited to the detection of 
chromosome aberrations greater than 5 to 10 Mb (12, 16, 45).                  
Many advantages exist for the use of array CGH in comparison with standard 
cytogenetics.  Due to its higher resolution, array CGH is able to determine with accuracy which 
genes are included in the region of copy number variation and may be able to identify specific 
genes which are disrupted by the breakpoints.  Even if a copy number variant is large enough to 
be detected by standard cytogenetic methods, accurate identification of the genes involved is 
often not possible without the use of array CGH (46).  Identifying the genes which may have 
altered expression can provide very important prognostic information and aid in the 
interpretation of results.  Studies have shown that the diagnostic yield of array CGH is 
significantly higher than that of classical cytogenetic analysis among individuals with various 
clinical indications, including MCA, autism spectrum disorders, and DD/ID.  Additionally, the 
cost of array CGH is often less than the combination of classical cytogenetic analysis and a 
targeted FISH test (16).                                                                
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Despite the many advantages, several limitations of array CGH must be considered when 
used in a clinical setting.  Array CGH generally has a longer turn-around time than classical 
cytogenetic analysis.  Some platforms may miss certain aneuploidies (such as XYY), marker 
chromosomes, and triploidies.  Array CGH is not able to detect the majority of balanced 
rearrangements that would be detectable by standard cytogenetics, but in 20% of balanced 
rearrangements there is a loss or gain of material which would be detectable by array CGH (46).  
It may identify mosaicism in some cases, but only at a 10% level for aneuploidies and at a 20-
30% level for other chromosomal abnormalities such as deletions and duplications (47); in 
comparison, standard cytogenetics is more accurate in the detection of mosaicism.  Array CGH 
cannot detect point mutations responsible for Mendelian disorders.  When a common aneuploidy 
syndrome is suspected due to the clinical presentation, array CGH may not be indicated as a 
first-tier test due to cost-effectiveness.  It is also not indicated when there is suspicion for a 
balanced translocation due to a history of miscarriages, as it cannot detect any truly balanced 
rearrangements (46).  The clinical acumen of the health care professional is highly valuable in 
determining the appropriate test to order, and in some cases classical cytogenetic analysis may be 
more efficient, cost-effective, and accurate.               
One important ethical consideration associated with array CGH is the potential to detect 
incidental findings which are clinically relevant but unrelated to the original diagnosis (46).  This 
may include detection of adult-onset disorders.  Adult-onset genetic disorders are defined as 
disorders which are usually phenotypically asymptomatic until the third decade of life or later.  It 
is the position of the National Society of Genetic Counselors (NSGC) that when the 
identification of gene carriers does not provide an avenue for therapeutic or preventative 
treatment in the prenatal or childhood periods, genetic testing must be carefully considered and 
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this decision should include genetic education and counseling (48).  For instance, array CGH has 
the potential to identify copy number losses containing tumor-suppressor genes which are 
associated with adult-onset cancer predisposition disorders.  This information would have 
important implications for medical management of the patient in the future but may only raise 
parental distress and anxiety in the present.  Even the incidental detection of a severe disorder 
with childhood onset, such as Duchenne muscular dystrophy, may not be information that is 
desired by the parents.   These findings are reported when they are detected, as the information 
may be useful for planning medical management and in some cases life-saving, but it raises a 
very important ethical consideration when ordering array CGH on a clinical basis.                                                                                     
Another challenge presented by the use of array CGH on a clinical basis is the 
interpretation of results.  Various studies have estimated that CNVs account for 5 to 12% of the 
total genome (49, 50) and that the average person has 800 or more benign copy number variants 
(46).  Therefore, CNVs may be classified as benign, pathogenic, or a variant of uncertain 
significance (VUS).  Because whole-genome oligonucleotide arrays are able to detect CNVs 
throughout the entire genome, a larger proportion of the CNVs detected will have unclear 
clinical significance (16).  In addition, providing prognostic information and recurrence risk 
based on results of array CGH may be challenging even when a CNV is clearly pathogenic.  This 
can be due to the limited availability of previous case reports or the incomplete penetrance and 
variable expressivity associated with a particular CNV.          
Determining an optimal resolution of an array CGH platform is critical in addressing the 
challenge of result interpretation.  Lower resolution platforms may miss smaller pathogenic 
abnormalities, while higher resolution platforms may increase detection of VUS.  Breckpot et al. 
compared 1 Mb and 244 kb array CGH platforms among patients with apparently syndromic 
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CHD, and concluded that causal CNVs were typically large and detected by a 1 Mb platform, 
while the 244 kb platform yielded a low frequency of causal variants and a high frequency of 
VUS (45).  We used a 135 kb platform in this study, but CNVs less than 300 kb with no genes or 
only genes with no known clinical significance are not reported by the laboratory, in order to 
limit the number of variants of unclear significance detected.                   
Characteristics of CNVs which are suggestive of pathogenic versus benign status are 
outlined below (16).  A summary of these criteria in algorithm form is shown in Figure 3 (45).  
This algorithm was utilized, in addition to the interpretation provided by the laboratory, to assess 
pathogenicity of all CNVs detected in our study.           
Characteristics suggestive of pathogenic status:     
• Identification of a similar CNV in an affected parent or relatives.   
• Overlap with a region of genomic imbalance identified in a database of affected 
individuals.  
• Overlap with a region associated with a known microdeletion or microduplication 
syndrome. 
• CNVs containing OMIM genes associated with disease, specifically genes associated 
with CHD or dominant, monogenic diseases with a known dosage effect (12).      
• Location in a gene-rich region. One proposed threshold is 20 genes, as the more genes are 
located in the region, the greater the probability that one is dosage-sensitive (12, 44).         
• Large size:  In a study by Thienpont et al., the median size of CNVs not previously 
reported as normal variants was approximately 6 Mb (12).        
• Deletions, homozygous deletions, and amplifications greater than one copy.        
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• De novo origin:  CNVs which are not detected by parental studies may be more likely 
pathogenic.  However, this may not be a strong indicator of pathogenicity for small 
CNVs, as the frequency of small de novo CNVs in normal individuals is not known (12).              
 
Characteristics suggestive of benign status:     
• CNVs identified in a healthy parent or relative.       
• CNVs within a region of genomic imbalance identified in a database of healthy 
individuals.        
• Location in a gene-poor region.  
• Duplications containing no regulatory elements and no genes which are known to be 
dose-sensitive.    
• Small size:  In one study, the median size of CNVs detected in normal individuals fell 
between 0.15 and 1.35 Mb (12).                       
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Figure 3. Assessment of Pathogenicity of Copy Number Variants (CNVs) (45)    
The phenotypic effects of a CNV are largely dependent on the dosage sensitivity of genes 
in the region of loss or gain.  Some genes are insensitive to dosage, and the deletion of one allele 
may have no effect.  Gene associated with autosomal recessive metabolic syndromes are one 
example; the deletion is only pathogenic if there is little to no protein produced.  Other genes are 
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highly sensitive to dosage, and the haploinsufficiency of these genes resulting from a deletion 
may cause a severe phenotype.  Although duplications are not as likely to be pathogenic, the 
increased dosage of certain genes can also have phenotypic effects.  Beaudet et al. postulated that 
many genes likely have intermediate sensitivity, allowing the phenotype to be modified by both 
genetics and environmental factors.  This hypothesis would be consistent with the incomplete 
penetrance and variable expressivity which are common to disorders associated with copy 
number variation (44).                                                        
1.1.5  Array CGH and DD/ID, MCA, and ASD                         
Array CGH is currently widely used as a diagnostic tool among patients with 
developmental delay/ intellectual disability (DD/ID), multiple congenital anomalies (MCA), 
and/or autism spectrum disorders (ASD).  Many studies have looked at the diagnostic yield of 
array CGH among patients with these clinical indications.  A summary of several important 
studies performed to date is provided below, including the inclusion criteria, array CGH 
platform, and detection rates of CNVs reported in each study.          
Lu et al. analyzed the results of array CGH among over 600 neonates with multiple 
congenital anomalies.  Because this study only included neonates, clinical features such as 
autism spectrum disorders or DD/ID were not yet identifiable.  For each subject included, one of 
three microarray platforms were utilized, including a V5 BAC-array, V6 BAC-array, and a V6-
oligonucleotide array; which had targeted genomic coverage with increasing resolution, 
respectively.  The detection rate was 27.1% among patients with dysmorphic features, MCA, and 
other clinical indications; 24.6% among patients with dysmorphic features with or without other 
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clinical indications, and 17.9% among patients with only MCA with or without other clinical 
indications(15).                
Shaffer et al. used a BAC array with 622 loci, targeted to known microdeletion 
syndromes, subtelomeric regions, and pericentromeric regions plus some backbone probe 
coverage, to test a broad population of over 8,000 individuals with indications including DD/ID, 
seizures, and various congenital anomalies.  They detected CNVs in 12% of this population, but 
after further assessment of pathogenicity of each CNV, only approximately 7% of this population 
was determined to have clinically significant chromosome abnormalities, 1% had benign 
polymorphisms, and 4% had variants of unclear clinical significance (51).  Wincent et al. tested 
160 patients with DD and/or MCA using array platforms with greater resolution, and identified 
CNVs which were not known to be normal variants in 22.5% of all patients.  A total of 13.1% of 
all CNVs identified were presumably causal to the patient’s phenotype.  A portion of their study 
population was tested using a 38K BAC-array and the remainder was tested with a 244K 
oligonucleotide-array (52).         
Miller et al. performed a meta-analysis of data which combined the findings of various 
studies including, in total, over twenty thousand patients with DD/ID, MCA and ASD.  Among 
these patients, array CGH had a diagnosis rate ranging from 15 to 20%, compared to a diagnostic 
yield of approximately 3% by using classical cytogenetic analysis alone (excluding Down 
syndrome and other recognizable chromosomal syndromes) (16).  In a similar study, Sagoo et al. 
also performed a meta-analysis of data including nearly 14,000 patients with learning disability 
and congenital anomalies.  They reported a lower diagnostic yield of 10%, and a false-positive 
rate of 7% (53).  It is clear from these studies that array CGH does result in an increased 
detection rate of chromosome abnormalities among patients with specific clinical indications.  
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However, it can also create a clinical challenge due to the detection of copy number variants 
which are benign or have unclear clinical significance.            
Based on the evidence delineated above for the increased diagnostic yield of array CGH, 
the American College of Medical Genetics (ACMG) has recently recommended in their Practice 
Guidelines that array CGH be ordered as first-tier test for individuals with any of the following: 
MCA not specific to a well-delineated genetic syndrome, apparently non-syndromic DD/ID, or 
autism spectrum disorder.  The goal of these recommendations is to increase the number of 
patients for which accurate and timely information about etiology, prognosis, and recurrence 
risks can be provided (46).                                  
         
1.1.6 Array CGH and Congenital Heart Defects    
Recently, various studies have investigated the clinical utility of array CGH among 
patients with CHD.  These studies have provided valuable information on potential candidate 
genes for CHD and the importance of submicroscopic chromosome abnormalities as a 
contributing etiology of CHD.  The benefit of utilizing array CGH in this population is that if a 
pathogenic and likely causal CNV is detected, additional prognostic information may be gained 
from previous case reports.  In addition, should parental studies confirm that a CNV is inherited, 
the recurrence risk would be 50% (for an autosomal CNV), but variable expressivity must be 
considered.  If the CNV is de novo, recurrence risk would be at the level of the general 
population (approximately 1%) rather than 2-5% (27).  Several studies done to date regarding 
array CGH for patients with CHD are listed in Table 1 and summarized below; the primary 
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difference between these studies is the inclusion criteria, such as age or the presence or absence 
of additional syndromic features.  Further research on this topic is warranted to further define the 
clinical utility of array CGH among specific populations of patients with CHD.                
Although the majority of CHD is considered non-syndromic, 25-40% of all cases of CHD 
are associated with additional congenital anomalies (7).  It has been hypothesized that 
submicroscopic chromosome abnormalities may be one underlying cause for these cases of 
apparently syndromic CHD without an identifiable cause.   Thienpont et al. was the first to 
analyze the use of array CGH among patients with apparently syndromic CHD.  They included 
60 patients of unspecified ages with CHD and other syndromic features (a major malformation, 
mental retardation or special education, and/or three or more minor physical anomalies).  These 
patients previously received a dysmorphology exam by a geneticist, classical cytogenetic 
analysis, and testing for specific genetic disorders if indicated and had no genetic diagnosis prior 
to array CGH.  Among this population, the detection rate of chromosome abnormalities was 30% 
using a 1 Mb platform; however only 17% were considered to be causal for CHD (12).  Breckpot 
et al. included the same study population, along with an additional 90 subjects with the same 
inclusion criteria, and reported a diagnosis rate of likely causal CNVS of 18% using a 1 Mb 
platform.  The only feature which had significant predictive value for the detection of 
chromosome abnormalities was dysmorphism (45).                                                           
Richards et al. also tested 20 children with apparently syndromic CHD, in comparison 
with a matched control population of 20 children with apparently isolated CHD, all of whom had 
a normal karyotype.  The detection rate of array CGH among children with CHD and any other 
congenital anomalies was 25%, but was nearly 50% among children with CHD and neurologic 
abnormalities (including developmental delay).  In this study, no chromosome abnormalities 
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were detected among children with isolated CHD, which led the authors to suggest that children 
with CHD and neurologic abnormalities should receive subtelomeric FISH or microarray along 
with classical cytogenetic analysis (11).  Goldmuntz et al. also looked at the detection rate of 
SNP-based oligonucleotide microarray among 58 patients of various ages with CHD and other 
congenital anomalies or dysmorphic features.  Patients with a known genetic diagnosis or 
chromosome abnormality detectable by classical cytogenetic analysis were excluded.  In this 
study population, the detection rate of potentially pathogenic CNVs was 20.7% (54).                    
In contrast with the previous studies, Erdogan et al. specifically analyzed the utility of 
array CGH among patients with apparently isolated CHD.  Their study cohort included 105 
Caucasian children diagnosed with an isolated CHD, who had no neurological problems or other 
features indicative of a syndrome at the time of diagnosis, and with the exception of one patient, 
had no family history of CHD.  Among this population, 18 CNVs were detected which were not 
previously reported as normal variants, yielding a detection rate of 17% (30).  As a subsection of 
a larger study including children with all types of birth defects, Lu et al. included 101 neonates 
with both apparently isolated and syndromic CHD, and reported a microarray detection rate of 
21.8% (15).      
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Table 1. Summary of studies to date on array CGH for patients with CHD       
Study 
Number of 
Subjects 
Phenotypic 
Features 
Total Detection 
Rate 
Likely Causal 
Detection Rate 
Thienpont et al. 2007 60 Syndromic  30% 17% 
Breckpot et al. 2010  
60 (above) + 
90 
Syndromic 28.7% 18% 
Richards et al. 2008 20 Syndromic  25% NA 
Goldmuntz et al. 2011 
(SNP-array) 
58 Syndromic  20.7%   NA   
Goldmuntz et al. 2011  
Previous 
literature 
review 
Syndromic  NA 19% 
Richards et al. 2008 20    Isolated  0% NA 
Erdogan et al. 2008 105 Isolated  17%  NA  
Goldmuntz et al. 2011 
40 + previous 
literature 
review 
Isolated  NA 3.6% 
Lu et al. 2008 101  
Neonates 
with CHD    
21.8% (clinically 
significant)  
NA   
  
There has been a wide range in the detection rates reported by previous studies, among 
both apparently isolated and syndromic CHD.  Some studies have suggested that the detection 
rate of CNVs among isolated CHD may be comparable to the detection rate among syndromic 
CHD (30).  However, there are often significant differences between the total detection rate by 
array CGH and the detection rate of likely causal CNVs.  To clarify the discrepancies, Breckpot 
et al. overviewed the literature on this topic and reclassified the causality of all chromosome 
aberrations detected by array CGH.  They reported a stark difference in the frequency of causal 
CNVs in each population, with a frequency of 3.6% among patients with apparently isolated 
CHD and 19% among patients with apparently syndromic CHD (45).  The collective data 
 38 
 
provided by these studies suggest a significant contribution of submicroscopic chromosome 
abnormalities to the etiology of CHD.  Although the contribution appears to greatest among 
populations with apparently syndromic CHD, the contribution among populations with 
apparently isolated CHD is not insignificant.         
1.2 SIGNIFICANCE 
Array CGH has recently been added as a first-tier test, along with classical cytogenetic 
analysis, at our institution for any neonate with CHD admitted to the Cardiac Intensive Care Unit 
(CICU).  This standard of care has been implemented on the basis of the recent ACMG 
recommendation to use array CGH as a first-line test for patients with multiple congenital 
anomalies, the documented increase in detection rate using array CGH for patients with CHD, 
and the known clinical benefit of obtaining an early diagnosis if an underlying genetic etiology 
exists.  The implementation of this standard of care provides a unique opportunity to assess the 
detection rate and clinical significance of array CGH results in this population.         
Previous studies have analyzed the clinical utility of array CGH among children and 
adults with CHD, but information regarding the detection rate and clinical efficacy of array CGH 
among neonates with CHD and as a first-tier test is still limited.  In studies which have included 
children and adults with CHD, extracardiac features are more readily apparent and in some cases, 
testing by array CGH was only performed after other genetic diagnoses were ruled out.  Our 
study contributes valuable information due to our unique study population, which includes any 
neonates with CHD admitted to the CICU within the first four weeks of life.  Due to presentation 
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in the neonatal period, this population may also have a higher prevalence of complex and 
clinically severe heart defects in comparison with previous studies.          
Compared to previous studies, we hypothesize a lower detection rate than the detection 
rate among populations selected for features that would not be apparent during the neonatal 
period, such as neurologic abnormalities (11).   Lu et al. included a very similar population of 
neonates with both isolated and syndromic CHD, so we hypothesize that our detection rate of 
CNVs will be similar to their detection rate of 21.8%.  Their study was a large, epidemiologic 
study which included neonates with all types of birth defects, so they understandably do not 
provide information regarding the prevalence of syndromic versus apparently isolated CHD in 
their population, and they report minimal information about specific CNVs (15).  Our study will 
supplement this previous data by including additional information regarding the presence of 
syndromic features among neonates with a CNV, as well as an assessment of the potential 
causality of each CNV detected.                                                          
It has been clear from previous studies that the frequency of causal CNVs is much higher 
in populations with apparently syndromic CHD (45), so it could be argued that chromosomal 
studies including array CGH should only be done for individuals with CHD and extracardiac 
abnormalities.  However, not all extracardiac abnormalities or dysmorphic features will become 
apparent during the neonatal period.  Features such as developmental delay and cognitive deficits 
only become apparent during childhood.  Dysmorphic features may be present at birth, but they 
may be very subtle and difficult to detect during the neonatal period.  Even after the neonatal 
period, some dysmorphic features which are indicative of a genetic syndrome may only be 
readily detected by a geneticist specializing in dysmorphology.  In cases with an underlying 
genetic etiology, it can be problematic to wait to pursue genetic testing until additional 
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extracardiac features are apparent.  Postponing a genetic diagnosis may also postpone effective 
management strategies and in some cases could have significant clinical consequences.  
Furthermore, it could also limit recurrence risk information available to parents when making 
reproductive decisions.  For these reasons, it can be problematic to base genetic testing decisions 
on the presence of extracardiac features, especially among neonates.  Our study will contribute 
valuable information to further clarify whether array CGH provides meaningful clinical 
information when ordered as a first-tier test for all neonates with CHD regardless of the presence 
of syndromic features.          
1.3 RESEARCH QUESTIONS AND HYPOTHESES  
The broad purpose of this study is to improve the clinical care of patients with a CHD, 
through increasing our knowledge of the genetics of CHD and determining the most efficient 
genetic testing strategy for this patient population.  This study is designed to supplement the 
findings of previous literature regarding the contribution of submicroscopic chromosome 
aberrations to the etiology of CHD, and specifically to explore the clinical utility of array CGH 
as a first-tier test for neonates with CHD.  Our study has both quantitative and qualitative aims 
which are discussed below.                                
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1.3.1 Aim 1:  Comparison of Detection Rates    
The quantitative aim of this study is to compare classical cytogenetic analysis and array 
CGH for the purpose of diagnosing chromosome abnormalities in neonates with a CHD.  The 
pertinent research question is the following:  Does the use of array CGH increase the detection 
rate of chromosome abnormalities among neonates with CHD above that of classical cytogenetic 
analysis?  To address this question, we will first determine whether the prevalence of 
chromosome abnormalities detected by classical cytogenetic analysis in our study population 
matches the reported literature rate at our institution.  A previous study performed at the CICU of 
Children’s Hospital of Pittsburgh of UPMC reported a detection rate of 14% among infants with 
CHD, using classical cytogenetic analysis and a total detection rate of 19% when including FISH 
for 22q11.2 (43).  We will then determine whether the addition of array CGH increases the 
detection rate of chromosome abnormalities.  We hypothesize that including array CGH as a 
first-tier test will significantly increase the detection rate of chromosome abnormalities in our 
study population.  Specifically, we hypothesize that array CGH will increase the rate of detection 
of chromosome abnormalities by 6% when compared to the previously reported 14% rate of 
chromosome abnormalities detected by classical cytogenetic analysis among infants in the CICU 
at Children's Hospital of Pittsburgh.    
1.3.2 Aim 2:  Assessment of Clinical Significance of CNVs   
One qualitative aim of this study is to assess the clinical significance of any CNVs 
detected by array CGH.  Determining the proportion of CNVs in our population with known 
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clinical significance versus those with uncertain clinical significance is important to accurately 
assess the clinical utility of array CGH as a first-tier test in this population.                                  
1.3.3 Aim 3:  Analysis of Phenotypic Data      
 An additional qualitative aim of this study is to analyze the dysmorphology exam results 
for any associations between specific CHDs, chromosome abnormalities, and extracardiac 
abnormalities.  We hypothesize that array CGH will be a useful first-tier diagnostic tool among 
an unselected population of neonates with CHD, including those with both apparently isolated 
and apparently syndromic CHD, as some patients with apparently isolated CHD may present 
with additional phenotypic features later in life.  However, we would expect based on the 
findings of previous studies that the detection rate of array CGH will be the greatest among 
neonates with apparent syndromic features.                                              
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2.0  MATERIALS AND METHODS  
This study was approved by the Institutional Review Board of the University of 
Pittsburgh prior to initiating the study.  Neonates under the age of four weeks diagnosed with 
CHD were ascertained through the CICU staff at Children’s Hospital of Pittsburgh of UPMC.  
Enrollment began on April 4, 2011 and continued through March 16, 2012 for the purposes of 
this study; enrollment is still ongoing for additional statistical analysis in the future.  Per standard 
of care, the majority of patients had classical cytogenetic analysis and array CGH ordered 
simultaneously by their attending physician, as well as a dysmorphology exam by a geneticist 
using a standardized form.  This study involved a chart review and data analysis; no additional 
testing was performed for the purposes of this study.   After obtaining consent from the patient’s 
family for access to medical records, including genetic test results, the data outlined below was 
collected by a chart review of the patient's medical records and was compiled into a secure, 
password-protected database.                                     
Results were obtained from any genetic tests ordered as standard of care, including 
classical cytogenetic analysis, array CGH, and FISH testing in some cases.  With the inclusion of 
array CGH, FISH testing for 22q11.2 microdeletion syndrome is no longer indicated as a first-
tier test for neonates admitted to the CICU at our institution, as genomic imbalances involving 
this region would also be detected by array CGH.  However, this test was still ordered in some 
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cases, and the results are included in our analysis.  Additional data obtained from medical 
records included gender, race, gestational age at birth, the first recorded height, weight, and head 
circumference percentiles, type of CHD, physical exam results, results of imaging studies (head 
ultrasound or MRI and renal ultrasound), and whether the patient had a formal genetics consult.                
Regardless of receiving a formal genetics consult, the majority of patients included in our 
study received a baseline dysmorphology exam by a geneticist, per standard of care.  The form 
used to evaluate for dysmorphology is included in the Appendix B.  The general fields of this 
exam include head shape, facies, hair, eyes, ears, nose, mouth, tongue, neck, cardiac features, 
genitourinary, chest, back, lungs, diaphragm, hands, feet, joints, skin, nails, neurologic, and other 
significant clinical features.  For each of these features, an assessment was made of normal, 
abnormal, or could not assess.  Any descriptions of dysmorphic features were also included in 
our database.  For patients who did not receive this standard dysmorphology exam by a 
geneticist, supplemental physical exam data were collected from Cardiology or CICU progress 
notes.                                    
All genetic testing ordered by the CICU was performed at the Pittsburgh Cytogenetics 
Laboratory, which is CLIA-approved and housed at Magee-Womens Hospital of UPMC.  To 
perform classical chromosome analysis, 5 mL peripheral blood was collected from the patient in 
a sodium heparin tube.  High-resolution G-banding was used to visualize prometaphase 
chromosomes at a 675 band-level resolution.  In each analysis, twenty cells were counted and six 
metaphase cells were analyzed and karyotyped.           
To perform chromosomal microarray analysis, 5 ml peripheral blood was obtained in an 
EDTA tube.  The microarray platform used by the Pittsburgh Cytogenetics Laboratory is the 
Roche NimbleGen 135K oligonucleotide array platform by SignatureChipOS™, version 2.0 
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(based on UCSC 2006 hg 18 assembly).  The accuracy and precision of this test has been 
established and verified in accordance with CLIA ’88 requirements.  This platform analyzes 
3397 loci at a 135 Kb resolution, and includes clones for subtelomeric regions, pericentromeric 
regions, and known genetic syndromes.  Any copy number variants which are less than 300 Kb 
in size, which do not contain any genes or contain only genes with no known clinical 
significance, are not reported.  Due to the limitations of microarray testing, this platform cannot 
detect balanced alterations, including reciprocal translocations, Robertsonian translocations, 
inversions, balanced insertions, or imbalances in regions which are not included on the platform.  
The accuracy of this specific platform for detecting mosaicism has not been established.          
The demographics of our study population, including race, gender, prevalence of each 
type of CHD, and prevalence of isolated versus apparently syndromic CHD, are tabulated and 
reported in our results.  Specific types of CHD were categorized by a standard classification 
system established by Botto et al.  In addition, each case was categorized as a simple, 
association, or complex heart defect; this categorization may be relevant to a syndromic versus 
isolated etiology but does not necessarily correlate with clinical severity.  Simple CHDs were 
defined as either an uncomplicated defect or a well-recognized unit of defects, such as TOF.  
Associations were defined as combinations of two to three simple defects.  Complex CHDs were 
defined as combinations of three or more defects, not including VSD or ASD (18).             
Categorization of isolated versus syndromic CHD was based on the presence of 
extracardiac features and dysmorphic features.  Dysmorphic features were defined as any 
physical features which were noted as abnormal on a dysmorphology exam.  Other features 
which were not noted to be abnormal were considered to be potentially normal variation; these 
are described in the case reports for patients with chromosome aberrations (Appendix A) but 
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otherwise were not reported.  In many cases, an overall assessment of dysmorphic appearance 
versus normal appearance was made by a Geneticist following the physical exam; this was also 
utilized in categorizing subjects as dysmorphic or non-dysmorphic.  Extracardiac abnormalities 
were defined by abnormal imaging studies or the presence of any congenital anomalies or 
additional diagnoses not related to the subject’s heart defect.  We did not include infections, 
features with a strongly suspected environmental cause, or additional cardiac abnormalities in 
this category.  Patients were categorized as having apparently isolated CHD if they did not have 
dysmorphic features or extracardiac abnormalities.  Patients were categorized as having 
apparently syndromic CHD if they had any dysmorphic features and/or extracardiac 
abnormalities.                           
Quantitative data analysis was performed to compare the detection rates of all types of 
genetic testing performed.  For the purposes of this study, the total detection rate of array CGH 
will include both abnormal CNVs and variants of uncertain clinical significance (VUS).  
Statistical analysis was performed using a McNemar’s test to compare the detection rates of 
classical cytogenetic analysis and array CGH.  This analysis was done to address our primary 
aim of determining whether array CGH significantly increases the detection of chromosome 
abnormalities in our study population.                                                         
Qualitative data analysis of each CNV detected is presented in tabular fashion in Tables 3 
and 4, and in case report fashion in Appendix A.  The pertinent clinical features discussed in 
each case report include gestational age, growth parameters, extracardiac abnormalities, and 
dysmorphic features, and an assessment of the potential pathogenicity of the CNV.  The 
following steps were taken to assess the pathogenicity of each CNV.  Genoglyphix Genome 
Browser® and DECIPHER, v5.1 were utilized to identify any genomic imbalance syndromes 
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which overlap with the region of interest and any genes which are deleted or duplicated (55, 56).  
For any genes identified, OMIM was used to determine the dosage sensitivity and any genetic 
syndromes associated with that gene.  The Database of Genomic Variants (DGV) was used to 
determine if the CNV is found in healthy individuals (57).  If parental studies were performed, 
information regarding whether the chromosome abnormality was inherited or de novo was also 
included.         
 48 
 
3.0  RESULTS  
3.1.1 Demographics  
The enrollment data and demographics of our study population are presented in Table 1.  
The gender ratio of our population was disproportionate in favor of males (62%) over females 
(38%).  Our population also disproportionately represented Caucasian subjects, as 62% of our 
subjects were Caucasian, not including those with race not specified.  Four patients (8%) were 
born prematurely at less than 37 weeks gestational age, although the vast majority of patients 
(92%) were greater than 37 weeks gestational age at delivery.   
Table 2.  Enrollment data and demographics    
 n % of total 
Subjects Enrolled 50  
Total Number Eligible 59  
 Eligible, Not Enrolled 9 /59 15.2% 
Sex   
 Male  31 62% 
Female 19 38% 
Race   
Caucasian 31 62% 
African American/ Black 1 2% 
Middle Eastern 2 4% 
Hispanic 1 2% 
NOS 15 30% 
Gestational Age   
< 37 weeks 4 8% 
> 37 weeks 46 92% 
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 Figure 4 depicts the prevalence of simple, association, and complex CHDs within our 
study population.  Based on our categorization criteria, defined in Section 1.4, the majority of 
subjects in this population (64%) had simple CHD.  Twenty-six percent of the population had an 
association of two to three individual types of CHD, and 10% had complex CHD.                       
 
Figure 4.  Complexity of CHD among all subjects enrolled 
3.1.2 Detection Rates  
The detection rates of each type of genetic test, including classical cytogenetic analysis, 
FISH for 22q11.2, and array CGH, are presented in Table 2.  Each detection rate was calculated 
by dividing the number of abnormal results in Column 2 by the number tested in Column 3.  The 
clinical significance and potential causality of each CNV are discussed in greater detail in 
Appendix A.   
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Table 3.  Detection rates by method of chromosome analysis 
Type of Testing N abnormal N tested % 
Total, any testing 13 48 27.1% 
Classical cytogenetic analysis AND 
Array CGH 10 39 25.6% 
Detected by standard chromosome analysis 2 39 5.1% 
Detected by array CGH only 8 39 20.5% 
Standard Chromosome Analysis 4 47 8.5% 
FISH (22q11.2) 1 10 10% 
Array CGH 9 40 22.5% 
Abnormal, Clinically Significant 3 40 7.5% 
Unclear Clinical Significance 6 40 15% 
                                                
Of the fifty subjects enrolled in our study, 48 subjects (96%) received at least one type of 
chromosomal analysis.  Of these subjects, 27% had some type of chromosome aberration.  Of all 
subjects tested by classical cytogenetic analysis, 8.5% were found to have a chromosome 
abnormality, including a balanced translocation, a large deletion, Trisomy 21, and mosaic 
Trisomy 21.  Of all subjects tested by array CGH, 22.5% (n= 9) had a CNV detected.  Only one 
22q11.2 microdeletion associated with DiGeorge syndrome was detected of the 10 subjects with 
FISH testing for 22q11.2, but it is important to note that any microdeletions in this region would 
have been detectable by array CGH as well.  Therefore, out of the total number of individuals 
with FISH or array CGH (n=44), the detection rate for microdeletions of 22q.11.2 would be 
approximately 2%.              
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Due to the recent implementation of ordering both classical cytogenetic analysis and 
array CGH as standard of care for neonates with CHD, 39 subjects (78% of all subjects enrolled) 
received both classical cytogenetic analysis and array CGH.  Of the subjects who received both 
tests, two subjects (5.12%) had a chromosome abnormality detected by classical cytogenetic 
analysis alone.  Array CGH detected one of these chromosome abnormalities (a large deletion) 
but not the other (a balanced translocation, which may not be pathogenic).  There were a total of 
8 CNVs detected by array CGH which were not detected by classical cytogenetic analysis.  
Therefore, the addition of array CGH increased the detection of chromosome aberrations by 
20.5%, to yield a combined detection rate of 25.6%.  Of the CNVs detected by array CGH, 
approximately 33% (n=3) had clear clinical significance, while 67% (n=6) had unclear clinical 
significance.                                                                        
McNemar’s test was utilized to assess whether this increase in detection rate by array 
CGH is statistically significant.  The null hypothesis was set as “the detection rates of array CGH 
and classical cytogenetic analysis are the same in our study population.”  The alternative 
hypothesis was set as “the detection rate of array CGH is significantly greater than the detection 
rate of classical cytogenetic analysis in our study population.”  This test analyzes paired data, 
and therefore only captures the 39 subjects who received testing by both array CGH and classical 
cytogenetic analysis.  There were a total of 9 discordant pairs: 8 subjects had a CNV detected by 
array CGH but a normal karyotype, and 1 subject had normal array CGH results but an abnormal 
karyotype (balanced translocation).  The two-sided p-value obtained using McNemar’s test was 
0.039.  Therefore, we can reject the null hypothesis at a significance level of α=0.05.         
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3.1.3 Phenotypic Features  
Specific criteria used to categorize dysmorphic features and extracardiac abnormalities 
are discussed above in Section 1.4.  Among our study population, there were a total of 21 
subjects with abnormal findings on head or renal imaging studies and a total of 15 subjects with 
other extracardiac abnormalities such as congenital anomalies or other diagnoses.  The combined 
frequency of any extracardiac abnormalities (including abnormal imaging studies and/or other 
extracardiac abnormalities) in our study population was 54% (n=27).  The frequency of 
dysmorphic features among our study population was 60% (n=30).  Of note, these findings were 
largely based on the assessment of Genetics providers, as 80% of our entire study population 
received some level of Genetics assessment.  In contrast, when only including assessments by 
Cardiology providers, only 14% (n=7) of all subjects enrolled were described as having 
dysmorphic features, while the remaining 86% of subjects were described as having “no obvious 
deformities” or as “non-dysmorphic” in appearance.                                      
Subjects with either dysmorphic features or extracardiac abnormalities were categorized 
as having apparently syndromic CHD, while subjects with neither dysmorphic features nor 
extracardiac abnormalities were categorized as having apparently isolated CHD.  The term 
“apparently” is used to indicate that in cases with additional features, there may not truly be a 
syndromic cause, and in cases with no additional features, other clinical features may become 
apparent later in life and the CHD may not be truly isolated.  According to these criteria, the 
frequency of apparently isolated CHD in our study population was 26% (n=13) and the 
frequency of apparently syndromic CHD in our study population was 74% (n=37).  Figure 5 
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depicts the prevalence of syndromic versus isolated CHD in our study population, subdivided by 
the presence of extracardiac abnormalities or dysmorphic features.             
 
Figure 5.  Prevalence of apparently syndromic versus apparently isolated CHD  
 
The prevalence of apparently syndromic versus apparently isolated cases of CHD, 
subdivided by the prevalence of chromosome aberrations within each group, is depicted below in 
Figure 6.  This includes chromosome aberrations detected by both classical cytogenetic analysis 
and array CGH.  The frequency of chromosome aberrations among subjects with apparently 
isolated CHD was approximately 8% (n=1).  The frequency of chromosome abnormalities 
among subjects with apparently syndromic CHD was approximately 32% (n=12).         
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Figure 6.  Frequency of chromosome aberrations among apparently syndromic and apparently 
isolated cases of CHD    
 
Figure 7 depicts the subdivision of subjects with apparently syndromic CHD, based on 
the type of phenotypic features exhibited.  Of subjects with apparently syndromic CHD, 19% 
(n=7) had only extracardiac abnormalities but no dysmorphic features noted; one (14%) of these 
subjects had a chromosome aberration.  Subjects with only dysmorphic features but no other 
congenital anomalies, diagnoses, or abnormalities on imaging studies made up 27% (n=10) of 
subjects with apparently syndromic CHD; among these, 3 (30%) had a chromosome aberration.  
Subjects with both extracardiac abnormalities and dysmorphic features were the largest group, 
comprising 54% (n=20) of all subjects with apparently syndromic CHD; 8 (40%) of these 
subjects had a chromosome aberration.                                               
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Figure 7.  Frequency of chromosome aberrations in neonates with apparently syndromic CHD, 
based on phenotypic features   
 
The frequencies of various types of CHD in our study population are presented below in 
Figure 8, as categorized by the Level III categories established by Botto et al. (18).  This figure 
also depicts the prevalence of apparently syndromic versus apparently isolated heart defects 
within each group.  Any associations or complex defects which had components in multiple 
categories are included under in “Other, Combined.”          
Conotruncal defects comprised the largest group of heart defects represented in our study, 
accounting for 40% of all subjects enrolled.  This prevalence would be even higher if it included 
the conotruncal defects which were a component of a complex defect.  Left ventricular outflow 
tract obstruction defects (LVOTO) are the next largest group, accounting for 16% of all subjects.  
Right ventricular outflow tract obstruction defects (RVOTO) accounted for 8% of the study 
population.  Six percent of the population had a septal defect, 10% had a septal and LVOTO 
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defect, 4% had a septal and RVOTO defect, and 14% had another combination of defects.  These 
are not reported individually, as each combination of defects was unique.      
        
 
Figure 8.  Frequency of each type of CHD subdivided by "syndromic" and "isolated" cases 
Figure 9 depicts the prevalence of each type of CHD among the thirteen subjects with a 
chromosome aberration detected by array CGH and classical cytogenetic analysis.  Again, 
conotruncal defects had the highest prevalence (38.5%) among these subjects.    
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Figure 9.  Frequency of each type of CHD among 13 subjects with a chromosome aberration 
     
Due to the presence of syndromic features or abnormal genetic test results, 19 subjects in 
our study population received a full Medical Genetics consult.  An additional 21 subjects 
received a baseline dysmorphology exam by a Geneticist per standard of care.  Therefore, a 
combined total of 80% of subjects enrolled in the study received some level of Genetics 
assessment.  Of the subjects who received a genetics evaluation, 9 had additional genetic testing 
for specific syndromes.  Four had findings of unclear clinical significance, which are briefly 
discussed in Section 1.6.  The remaining five subjects either had normal test results or tests 
which were pending at the time of this report.  Of note, two subjects with findings of unclear 
clinical significance by array CGH did not receive a formal Genetics consult.                    
3.1.4 Chromosome Aberrations  
All chromosome aberrations detected in this study, including large abnormalities detected 
by classical cytogenetic analysis and CNVs detected by array CGH, are recorded in Table 3.  
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This table includes basic information used in the assessment of pathogenicity of each CNV, such 
as size and chromosomal location, inheritance, number of OMIM genes in the region of genomic 
imbalance, and availability of case reports of similar CNVs.  A more detailed assessment of 
causality for each CNV detected by array CGH is included in Appendix A.                
Phenotypic features of all patients with a chromosome aberration detected by classical 
cytogenetic analysis or array CGH are presented in Table 4, including categorization of each 
subject’s CHD, type of phenotypic features present, and any abnormalities detected on imaging 
studies.  These features are discussed in greater detail in Appendix A.                
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Table 4.  Description of all chromosome aberrations detected 
Patient 
ID Region 
Gain/ 
Loss 
Size 
(Mb) Start End Inheritance 
# 
OMIM 
Genes 
Previous 
Case 
Reports 
Clinical 
Significance 
per Lab 
Array CGH  
110 3p23p22.2 Loss 7.7 30,940,540 38,605,621 -- 35 Yes Abnormal 
118 16q21 Gain 0.683 57,098,728 57,781,710 M 2 No VUSc 
119 3p26.3 Loss 0.295 1,124,286 1,419,226 -- 1 No VUS 
121 1q21.1 Gain 1.19 144,998,070 146,193,043 -- 9 Yes Abnormal 
127 2q21.3 Loss 0.358 135,489,180 135,847,346 -- 2 No VUS 
128 16p11.2 Loss 0.535 29,564,890 30,100,123 -- 18 Yes Abnormal 
132 22q12.3 Loss 0.346 32,191,531 32,537,463 P 1 No VUS 
140 3p14.1 Loss 1.36 67,719,379 69,080,808 -- 2 No VUS 
141 20p11.21 Gain 0.398 25,016,046 25,414,542 -- 5 No VUS 
Classical Cytogenetic Analysis   
102 
46,XX,t(6;10) 
(p21.2;15) 
BTb --- P NA -- ND 
110 
46,XY,del(3) 
(p22.2p23) 
Loss 
Also detected by array CGH, listed 
above 
-- 35 Yes Abnormal 
126 
Mosaic 
Trisomy 21 
Gain 
Prenatal diagnosis, level of mosaicism 
undetermined 
-- NA Yes Abnormal 
143 Trisomy 21 Gain Prenatal diagnosis -- NA Yes Abnormal 
FISH for 22q11.2     
148 Microdeletion 22q11.2 Loss Prenatal diagnosis -- -- Yes Abnormal 
a M- maternal; P- paternal, -- not determined  
b Balanced Translocation     
c 
VUS- Variant of Uncertain Significance      
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Table 5.  Phenotypic features of patients with chromosome aberrations 
Patient 
ID Sex 
Types of CHDa 
Phenotypic 
Features Imaging Studies 
Level I (Detailed) 
Level III 
(Broad) 
Complexity 
Extracardiac 
Features or 
Dysmorphic 
Features 
Head U/S or 
MRI 
Renal 
U/S 
102 F TOF Conotruncal Simple Extracardiac Normal Normal 
110 M 
Double Outlet Right 
Ventricle, TOF type 
 
Pulmonary Valve Stenosis 
Conotruncal Simple Dysmorphic Normal NDa 
118 M 
D-TGA with noninlet VSD 
and RVOTO (AS and 
COA)   
 
Double Outlet Right 
Ventricle, TGA type 
Conotruncal Association Both    Abnormal Abnormal 
119 M ASDs, multiple Septal Simple Both Normal Abnormal 
121 F HLHS with intact 
ventricular septum LVOTO 
Simple Dysmorphic Normal Normal 
126 M 
AVSD with RVOTO 
 
HLHS with intact 
ventricular septum 
  
DORV, TGA type   
AVSD 
 
LVOTO 
 
Conotoruncal 
Complex Dysmorphic  Normal Normal 
127 F Patent Ductus Arteriosus, 
Patent Foraman Ovale -- 
Simple 
 
Both 
Normal Abnormal 
128 F TOF Conotruncal Simple Both Normal Abnormal 
132 F 
Single Ventricle, Double 
Inlet Left Ventricle type, 
nos   
 
Pulmonary Valve Stenosis  
 
VSD     
Single 
Ventricle/ 
Complex 
 
RVOTO 
 
Septal 
Complex Both Normal Normal 
140 F Atrioventricular Septal 
Defect with RVOTO  AVSD 
Simple None Normal Normal 
141 M HLHS    LVOTO Simple Both Normal Abnormal 
143 M 
VSD  
          
Pulmonary valve stenosis  
RVOTO Association Extracardiac Abnormal ND 
148 F 
Interrupeted aortic arch, 
type B 
 
VSD, conoventricular type 
Conotruncal    Association Both Abnormal Abnormal 
a Type of CHD is presented based on Level I (detailed) and Level II (broad) category [Botto].   
b Not done              
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4.0  DISCUSSION 
The question of whether array CGH should be included as a first-tier test for neonates 
with CHD is complex.  The spectrum of data collected for this study, and from previous studies 
done to date, is broad and there are many factors to consider in the interpretation of results.  This 
discussion provides a comprehensive review of the significance of our results, regarding the 
contribution of chromosome aberrations as one cause of CHD and the efficacy of array CGH as a 
first-tier test among neonates with CHD.  The conclusions drawn from our results which address 
the primary aims of the study are presented below.  The strengths and limitations of our study, 
ethical considerations, and future directions are discussed in Sections 2.1.4 and 2.1.5.                            
4.1.1 Aim 1: Comparison of Detection Rates    
One aim of our study was to determine if the prevalence of chromosome abnormalities 
detected by classical cytogenetic analysis matched the 14% detection rate which was previously 
reported at our institution (43).  Of all subjects tested by classical cytogenetic analysis, the 
detection rate by this method of chromosome analysis alone was only 8.5%.  Although this is a 
lower prevalence of large chromosome abnormalities than previously reported at our institution, 
it is a reasonable prevalence in comparison with the literature prevalence of 8 to 13% of large 
chromosome abnormalities among individuals with CHD  (2, 3).   It is also important to note that 
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the total detection rate of chromosome aberrations among our study population was 27.1%, as 
detected by classical cytogenetic analysis, FISH, and array CGH combined.  This includes all 
findings, regardless of clinical significance, but still provides strong evidence that chromosomal 
causes are very important to the overall etiology of CHD and warrant further research.      
The primary aim of our study was to determine whether array CGH significantly 
increases the detection rate of chromosome abnormalities in comparison to classical cytogenetic 
analysis.  We hypothesized that the addition of array CGH would increase detection by 6% over 
the previously reported 14% detection rate by classical cytogenetic analysis alone among 
neonates in the CICU at our institution (43), to yield a total detection rate of at least 20%.  Our 
actual detection rate was even greater than hypothesized:  among all subjects receiving both 
tests, the actual combined detection rate was 25.6%.  Array CGH increased detection by 20.5%, 
as only 5.1% of the subjects receiving both tests had a chromosome abnormality detected by 
classical cytogenetic analysis.  In addition, the total detection rate of CNVs among all subjects in 
our study tested by array CGH (22.5%) was very similar to that which was previously reported 
by Lu et al. among neonates with CHD (21.8%) (15).  Using McNemar’s test of significance, we 
obtained a p-value of 0.039, which reflects a low probability of observing our data under the null 
hypothesis of equal detection rates.  We can reject the null hypothesis, and conclude that within 
this population of neonates with CHD, the detection rate of array CGH is significantly greater 
than that of classical cytogenetic analysis alone.          
There are several limitations of our population which may have affected the statistical 
analysis of our data.  First, our sample size was relatively small:  a total of 50 subjects were 
enrolled of the 59 patients who were eligible for participation.  In two cases, the parents declined 
participation in the study.  In three cases, the parents were contacted but were discharged prior to 
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signing the consent; in some cases parents were contacted via telephone but consent forms were 
not returned by mail.  Three patients passed away during their admission to the CICU and we 
elected not to contact these parents regarding participation.  One patient could not be enrolled 
due to a language barrier and the lack of a consent form in the native language of the parents.       
Second, there was a significant lack of consistency in ordering array CGH.  The standard 
of care to order both classical cytogenetic analysis and array CGH upon admission is very recent 
and was being implemented only as the study commenced.  Therefore, only 78% of all subjects 
enrolled received both tests.  The remainder received only one or neither test; some received 
FISH for 22q11.2 instead of array CGH.  Because the test results can be categorized as non-
independent, paired binomial data which is best represented in a contingency table, McNemar’s 
was the most pertinent to our analysis.  However, due to the paired nature of this test, our 
effective sample size was limited to 39 subjects.  Results from subjects who did not receive both 
tests were non-paired and could not be captured.                                           
In addition, three subjects had chromosome abnormalities detected prenatally by classical 
cytogenetic analysis or FISH analysis and did not receive testing by array CGH and therefore 
could not be captured in our statistical analysis.  These subjects had Trisomy 21, mosaic Trisomy 
21, and microdeletion 22q11.2.  Had the subjects received chromosome analysis by array CGH, 
it is very likely that each abnormality would have been detected by array, with the possible 
exception of mosaic Trisomy 21.  By assuming all of these subjects had abnormal array CGH 
results, the number of discordant pairs detected by array CGH only would have increased to 9 
due to the 22q11.2 microdeletion, which would have lowered the p-value to 0.013.  By assuming 
each abnormality except mosaic Trisomy 21 would have been detected, the number of discordant 
pairs detected by classical cytogenetic analysis would have also increased to 2, and increased the 
 64 
 
p-value to 0.041.  However, in either scenario, our p-value would have still been statistically 
significant to reject the null hypothesis.                                                
We report a significant increase in detection rate by utilizing array CGH among neonates 
with CHD.  It is important to recognize that this detection rate is within a unique study 
population, which does not include children or infants who were diagnosed after 4 weeks of life.  
It also does not include miscarriages, stillborns, or infants admitted to the CICU after 4 weeks of 
age, which may have milder cases of CHD.  Additionally, neonates with an aneuploidy, such as 
Trisomy 13 or 18, are likely to receive palliative care instead of surgical treatments and therefore 
are not likely to be admitted to the CICU.         
Another important consideration is that our detection rate incorporates all CNVs detected, 
both with known clinical significance and unclear clinical significance.  All results are included 
because of the uncertainty which is intrinsic to interpreting the clinical significance of CNVs.  
CNVs with unclear clinical significance may in fact be causal for the patient’s CHD, but the 
available data may not be sufficient to draw this conclusion at the present time.  Thus, it is 
important to identify and reassess the potential causality of each CNV over time as more genes 
implicated in CHD are identified.  In contrast, CNVs with known clinical significance may not 
be causal for the patient’s CHD, but may still be clinically relevant and potentially causal for 
additional syndromic features.  This is exemplified by patients 121 and 128 (see appendix A).  
Because we have reported all CNVs, this detection rate is likely inflated above the actual 
detection of pathogenic results.  However, it is important to consider the clinical impact of the 
total detection rate, because all cases in which a CNV is detected will warrant the assessment of 
a geneticist to evaluate the clinical significance and consider additional genetic testing.        
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4.1.2 Aim 2: Clinical Significance of Array CGH Results     
Case reports for all chromosome aberrations detected by array CGH are presented in 
Appendix A.  There are several trends among these case reports which illustrate both the 
advantages and the clinical challenges of utilizing array CGH in this population.  There were 
several subjects with a CNV detected only by array CGH, which has been previously associated 
with disease and therefore provides clinically relevant information for both the physicians and 
the patient’s family.  However, approximately two-thirds of the CNVs detected in our population 
by array CGH had unclear clinical significance.  Interpreting the clinical significance of results 
may pose a significant challenge when there is a limitation of data which can aid in 
interpretation. In addition, even among CNVs which are clearly pathogenic, it may still be 
difficult to determine whether the CNV is causal for the heart defect or only the additional 
extracardiac abnormalities.        
One factor which limited the interpretation of CNVs in our study was the lack of parental 
testing, which can be attributed to multiple causes.  In some cases, the patient did not receive a 
Genetics consult and may not have been offered parental studies.  Other subjects were offered 
testing, but have not yet elected to pursue testing at the time of data collection; if the data is re-
analyzed in the future, these parental studies may be completed and may aid in interpretation.  
Another factor which currently limits the interpretation of array CGH results is that databases of 
CNVs detected in disease and healthy populations are still relatively new.  When the CNV has 
not been previously reported in any databases, it can be very difficult to interpret significance.  
As array CGH continues to be utilized among patients with various indications, the available 
data which can be used for interpretation will certainly increase as well.                  
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To address the challenges of interpreting array CGH results, the involvement of Medical 
Genetics is crucial.  A physical exam by a geneticist specializing in dysmorphology may be 
helpful in determining the syndromic or isolated nature of the CHD.  If it appears to be 
syndromic in nature, it is important to consider whether the CNV is likely causal for the 
syndromic features or whether the features are suggestive of a specific monogenic disorder, in 
which case additional genetic testing can be ordered.  If case reports of similar CNVs exist in the 
literature, the phenotypic features of the patient can be compared with previous reports.  Finally, 
the involvement of Medical Genetics in cases with a VUS will ensure that parental studies are 
offered, recurrence risk is discussed, and appropriate follow-up is provided to re-evaluate 
phenotypic features and the potential causality of the CNV in the future.                                
 Despite these challenges, there are many advantages of using array CGH as a first-tier 
test.  First, one third (n=3) of all CNVs detected by array CGH were clearly abnormal, for a 
detection rate of 7.5% for clinically significant CNVs among all subjects tested by array CGH.  
Not all of these CNVs were necessarily causal for the patient’s CHD, but each had definite 
clinical significance.  Patient 110 had a large deletion of 3p23p22.2 which was also detected by 
classical cytogenetic analysis; detecting this deletion led to the diagnosis of several monogenic 
syndromes.  It was likely causal for the patient’s CHD, as several genes in this region have been 
associated with heart defects.  Patient 121 was diagnosed with 1q21.1 duplication syndrome; this 
syndrome is associated primarily with DD/ID and dysmorphic features, but there have been case 
reports of heart defects (aortic valve abnormalities) associated with 1q21.1 duplication syndrome 
(58).  Patient 128 was diagnosed with 16p11.2 microdeletion syndrome.  This syndrome is also 
associated with neurologic manifestations, primarily autism spectrum disorder; there has been at 
least one case report of a heart defect associated with this syndrome (59).  Each of these cases is 
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discussed in greater detail in Appendix A.  In each of the above cases, the use of array CGH 
provided valuable information for the continued monitoring of these patients.                                
 In cases in which a pathogenic CNV is detected by array CGH, the early diagnosis can 
provide valuable information regarding recurrence risk and sometimes medical management 
information for both the patient and their family members.  If the CNV is determined to be 
parental in origin, the recurrence risk would be 50% for each subsequent pregnancy; this is 
significantly different from the standard 2 to 5% recurrence risk provided based on an 
assumption of multifactorial etiology.  One example in which critical management information 
was provided for both the patient and their family was Patient 110.  This patient had a deletion 
including genes associated with cardiac conduction defects, as well as MLH1, associated with 
Lynch syndrome.  Parental studies could not be completed immediately following the patient’s 
diagnosis, but because of the clinical severity of the disorders associated with this deletion, a 
baseline cardiology evaluation and colonoscopy was recommended for all at-risk family 
members until further testing could be completed.                          
Even the detection of a VUS can provide clinically useful information.  In many of the 
cases discussed in Appendix A, there were no previous reports of similar CNVs, gene dosage 
effects were unclear, and parental studies were not completed.  Therefore, it is still possible that 
the CNV is pathogenic but the mechanism is unknown; the continued monitoring of the patient 
for any additional syndromic features is still important.  If additional phenotypic features become 
apparent later in life, the patient can be re-evaluated to determine if the CNV is likely causal or if 
additional genetic testing is warranted.  In many cases within our study, patients with a VUS did 
present with additional phenotypic features which could indicate a syndromic etiology.       
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In addition, there are some cases in which a deletion with unclear clinical significance 
encompasses a gene associated with an autosomal recessive disorder.  In most cases, this patient 
is simply an asymptomatic carrier for this disorder.  However, in some rare cases, the patient 
may carry a mutation in the other allele and would be affected.  For this reason, once such a 
deletion has been identified, this patient can be monitored in the case that phenotypic features 
indicating a mutation in the other allele would become apparent.  In these rare cases, early 
detection of the CNV may greatly minimize the time needed to reach a diagnosis.  Knowing 
carrier status for the disorder may also be useful for the patient in the future at the time of child-
bearing.  If testing is clinically available, their partner would have the option of genetic testing 
for mutations in that gene in order to determine their risk of having a child with the disorder.                        
4.1.3 Aim 3: Phenotypic Features  
The third aim of our study was to evaluate the relationship between chromosome 
abnormalities and phenotypic features among our study population.  Phenotypic features, 
including the type of heart defect and the presence of dysmorphic features and other extracardiac 
abnormalities, have been frequently used in the past as criteria to determine which patients 
should receive genetic testing.  Classical cytogenetic analysis and array CGH are now utilized as 
first-tier tests for any neonates with CHD at our institution regardless of additional phenotypic 
features.  However, the presence of syndromic features is still important in determining which 
patients should receive a Medical Genetics consult and whether additional investigation into 
monogenic syndromes is warranted.                                           
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The majority of subjects enrolled in our study did exhibit additional findings in the 
neonatal period, including either dysmorphic features or other extracardiac abnormalities, to 
yield a very high prevalence (74%) of apparently syndromic CHD.   In comparison, it has been 
reported in previous literature that 25 to 40% of patients with CHD have additional birth 
anomalies (7, 11).  Several additional factors are likely to have contributed to the high 
prevalence of apparently syndromic CHD in our population.  First, by virtue of admission under 
four weeks of age, the neonates include in our study have a more severe clinical presentation, 
which may increase the frequency of syndromic CHD compared to a population of individuals 
diagnosed at a later age with less severe CHD.  Second, our criteria for assessing whether any 
syndromic features were present were quite broad in order to maintain consistency and avoid 
subjectivity.  Not all subjects enrolled received a full evaluation by a geneticist, but any subject 
with any dysmorphic features and/or extracardiac abnormalities were considered to have 
syndromic CHD.  In addition to congenital anomalies, we included any abnormalities detected 
on imaging studies, additional diagnoses, or features noted to be “abnormal” on a 
dysmorphology exam by a geneticist.  These broader criteria ensure the inclusion of all 
individuals with features suggestive of a syndromic etiology.  Sometimes these features are 
unclear in the neonatal period, and therefore the disadvantage to these criteria is that patients 
may be included who will later be considered to have isolated CHD.          
Based on our data to this point, array CGH had a much greater detection rate among 
patients with apparently syndromic CHD.  Of the 13 subjects with a chromosome aberration, 12 
were categorized as having apparently syndromic CHD based on our criteria.  Three of the 
subjects with apparently syndromic CHD and a chromosome aberration detected had dysmorphic 
features but no other extracardiac abnormalities, while only one had extracardiac abnormalities 
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but no apparent dysmorphic features.  Although our sample of patients with chromosome 
aberrations was quite small, these findings suggest that dysmorphic features, as identified by a 
geneticist, may be equally as useful as extracardiac abnormalities in predicting whether a 
chromosome abnormality will be detected.   
Regarding the prevalence of dysmorphic features among our population, 60% of the 
entire study population had at least one abnormal feature on an exam by a geneticist, and 20% 
had only dysmorphic features but no extracardiac abnormalities.  This prevalence may have been 
even higher had all subjects received an exam for dysmorphology.  Some of these patients may 
not have an overall dysmorphic appearance, but did have features noted to be abnormal which 
warrant reassessment in the future.  However, it is important to note that, although 60% of our 
study population had dysmorphic features when assessed by a geneticist, only 14% were noted to 
have dysmorphic features in the clinical notes by Cardiology providers.  This discrepancy may 
be attributed to the fact that features can be very subtle, especially in the neonatal period, and 
may only be recognized by a geneticist who has expertise in dysmorphology.       
The increased detection of CNVs among subjects with apparently syndromic CHD could 
lead to the conclusion that only neonates with additional features should receive array CGH as a 
first-tier test, similar to recommendations made in previous studies for older individuals with 
CHD.  However, this conclusion could be problematic for several reasons.  First, the prevalence 
of syndromic CHD was 74% among our population; the increased detection rate of CNVs among 
this group may simply reflect this distribution.   This trend may not persist if the criteria for the 
categorization of apparently syndromic CHD were more stringent.  In addition, the detection of 
dysmorphic features in our population was much greater when based on the assessment of a 
geneticist.  For example, Patients 110 and 121 both had a pathogenic CNV and had dysmorphic 
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features which were only identified by a geneticist.  Basing testing on the presence of syndromic 
features, especially among patients who are not evaluated by a geneticist, may result in missing 
patients with truly syndromic CHD caused by a chromosome abnormality.                                 
As exemplified by our results, both dysmorphic features and other extracardiac 
abnormalities are important in assessing syndromic versus isolated CHD.  To identify occult 
extracardiac features, it has been previously recommended that all patients with CHD receive a 
routine head ultrasound and renal ultrasound (43).  It would be ideal for every neonate with CHD 
to have an evaluation by a geneticist to identify dysmorphic features and assess whether the 
CHD appears isolated or syndromic in nature.  However, it may not be feasible for every infant 
with CHD to receive a Medical Genetics consult.  One reasonable approach may be to have any 
neonate with CHD and congenital anomalies, abnormal imaging studies, or suspected 
dysmorphology receive a physical exam by a geneticist to determine if any testing in addition to 
classical cytogenetic analysis and array CGH is warranted.                                                                   
4.1.4 Additional Challenges and Considerations 
Through the course of our study, several systemic challenges were discovered which may 
have direct impact on the efficacy of array CGH in this population.  First, not all subjects were 
tested by both array CGH and classical cytogenetic analysis as this is a newly implemented 
standard of care.  In addition, although a large portion of our study population (38%) did have a 
formal inpatient genetics consult due to the presence of syndromic features or abnormal genetic 
test results, there were two patients with a VUS for which a Medical Genetics consult was not 
ordered.  Without the involvement of Medical Genetics, parental studies may not be obtained, 
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which limits interpretation of results, and the family may not be provided with appropriate 
counseling and follow-up.  These findings suggest that if array CGH is to be ordered by 
cardiology providers as a first-tier test, it is important to establish an algorithm which would 
ensure that both tests are ordered and that families are provided with proper follow-up for 
abnormal results.                       
Another challenge which became apparent through our study was the lack of consistent 
entry of genetic results in electronic medical records.  This may have been one factor which 
contributed to the instances in which patients with a VUS did not have a Medical Genetics 
consult, as the results of genetic testing may not have been brought to the attention of the 
attending physician.  Any genetic test reports are sent to the ordering physician, but are not 
frequently listed in the part of the electronic medical record system which is utilized by most 
providers for the most up to date clinical records.  When there is a transfer of care from the 
CICU providers to the NICU or Cardiology, the current physician may not have electronic access 
to the results.  The laboratory is currently working on developing a solution to this problem, 
which will likely include the direct entry of all genetic test results from the laboratory into the 
electronic medical record system, to ensure ease of access by all healthcare providers.                            
One important consideration when utilizing array CGH among neonates with CHD is that 
this test cannot detect any single gene defects.  Tests for specific monogenic disorders may be 
warranted in addition to array CGH when the CHD appears to be syndromic but it cannot be 
attributed to a chromosomal etiology.  To this point, eight subjects in our study received 
additional genetic testing.  Of these, three had normal test results and one had tests pending at the 
time of this report.  Four had a VUS on single gene testing.  Of these, two were detected on a 
Pancardio Panel. One of these patients had a VUS in three genes including ANKRD1, CRYAB, 
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and TTN; all of which are expressed in cardiac muscle and have been implicated in 
cardiomyopathy.  The other patient had a VUS in the gene DSG2.  This VUS was noted to be 
likely pathogenic, and mutations in this gene are associated with forms of arrhythmogenic right 
ventricular dysplasia and dilated cardiomyopathy (60).  This subject was diagnosed with dilated 
cardiomyopathy and two ASDs.  Another subject had clinical indications including dysmorphic 
features, lax skin, tortuous carotid arteries, and umbilical hernia along with a VSD and COA.  
This subject had a sequence variant detected in TGFBR1, one gene associated with Loeys-Dietz 
syndrome; this variant resulted in the missense substitution of an aspartic acid with a tyrosine.  
Another subject had a sequence variant in the gene G6PC which is associated with glycogen 
storage disease type IA; this VUS was considered unlikely to be pathogenic.  This is an 
autosomal recessive syndrome, so if the VUS were pathogenic, this subject would only be a 
carrier for the disorder (60).                
There has recently been debate regarding whether array CGH should replace classical 
cytogenetic analysis as the only first-tier test among patients with various clinical indications.  
The benefits of utilizing array CGH only is that the cost would be substantially lower and the 
majority of causal abnormalities would be detected; in our study at least 11 of the 13 total 
chromosome aberrations would have been detected by array CGH alone.  However, two 
diagnoses may not have been made, including mosaic Trisomy 21, which was likely causal, and 
a balanced translocation, which may not have been causal.   The detection of mosaic Trisomy 21 
is dependent on the level of mosaicism; this patient (Patient 126) did not have array CGH so it is 
not clear whether it would have been detected.  The detection of balanced translocations does 
provide very important reproductive information for parents due to the risk for unbalanced 
translocations.  In other cases, balanced translocations may be causal for CHD due to the 
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disruption of important genes.  Our sample size is too limited to draw conclusions on this matter, 
and further studies with a larger sample size are warranted to determine the optimal testing 
strategy.  One possible solution would be to utilize classical cytogenetic analysis as a second-tier 
test in cases with normal array CGH results but features suggestive of a chromosomal syndrome 
(i.e. parents with multiple miscarriages); this may maximize cost effectiveness with a minimal 
decrease in the efficiency of diagnosis.  At this point, it seems that the most conservative strategy 
to ensure the detection of causal chromosome abnormalities among neonates with CHD is the 
simultaneous use of classical cytogenetic analysis and array CGH.                                                                         
Various ethical and psychosocial considerations were exemplified by this study and are 
important to recognize when ordering array CGH on a clinical basis.  First, array CGH has the 
potential to detect adult-onset conditions in a child with an unrelated clinical indication.  One 
example in our study was that one subject (Patient 110) received the diagnosis of Lynch 
syndrome, also known as Hereditary Non-Polyposis Colorectal Cancer Syndrome, due to a 
deletion encompassing the gene MLH1.  This is an adult-onset cancer predisposition syndrome.  
In families affected by Lynch syndrome, testing is not generally recommended until age 18 when 
the individual provides informed consent, as there are no associated childhood cancers.  De novo 
inheritance was suspected in this case, but it has not yet been confirmed by parental studies.  Due 
to the absence of a history of Lynch syndrome cancers in this family, it is unlikely that the 
diagnosis would have ever been suspected.  The advantage of making this diagnosis via array 
CGH is that an increased screening regimen will be recommended for this patient in the future, 
which may lead to the prevention of a malignancy.  Increased screening was also recommended 
for at-risk family members until additional testing provides confirmation that the deletion was de 
novo.  The disadvantage of making this diagnosis is that it may cause a psychological burden on 
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the patient and his parents when no steps to reduce cancer risk can be taken at the present.  This 
information could be undesired or overly burdensome for parents who bear the additional burden 
of coping with the diagnosis of CHD.                               
An important psychosocial aspect of the clinical use of array CGH is that making sense 
of uncertain results is challenging not only to the physicians but also to the patient’s family.  It 
may be very difficult for families to understand the meaning of a VUS.  Even among subjects 
who carry a CNV associated with a contiguous gene syndrome, the variable expressivity and 
reduced penetrance which are characteristic of these syndromes can be difficult concepts for 
families to understand.  In these cases, recurrence risk could be as high as 50%.  However, in 
actuality it may be much lower due to reduced penetrance, but the exact degree of penetrance 
may not be well-defined.  These families are already coping with a very stressful situation 
including the critical illness of their child and a strenuous course of hospitalizations and 
surgeries.   In these cases, the genetic counselor plays a crucial role by explaining these 
challenging concepts with clarity and empathy and providing appropriate follow-up.  Research 
on the psychosocial impact on parents from receiving results with uncertain significance within 
this population is warranted.                   
4.1.5  Future Directions                                             
There are various limitations to our study which can be addressed in the future through 
continued enrollment, data collection, and analysis.  One limitation was that this study was 
completed within the span of one year, which limited both the sample size and the availability of 
data from parental studies and follow-up genetics appointments.  In several cases with apparently 
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syndromic CHD, additional genetic testing for monogenic disorders was not yet completed at the 
time of data collection.  If this study is continued, the results of any additional genetic testing can 
be included to determine if any subjects, specifically those with a VUS detected by array CGH, 
have been given additional diagnoses which may explain their CHD.                                               
The total sample size (n=50) and the small sample size of subjects who received both 
classical cytogenetic analysis and array CGH (n=39) are both relatively small.  We plan to 
continue enrolling subjects in order to increase the total sample size.  In addition, the percentage 
of subjects receiving both tests should increase over time as this standard of care becomes more 
established.  We will reanalyze the data in the future to determine if the increase in detection by 
array CGH remains as high as the detection rate based on the data to this point.  A larger sample 
size will facilitate a more statistically significant analysis of the prevalence of CNVs with 
clinical significance versus uncertain clinical significance.  In addition, type of heart defect did 
not seem to have predictive value for isolated versus syndromic CHD, as the distribution of 
syndromic and isolated cases by type of CHD was fairly similar across all categories (Figure 8), 
but a larger sample size would facilitate additional investigation.  A larger sample size would 
also allow us to determine whether the prevalence of CNVs varies by type of CHD.                                              
Finally, we reported a prevalence of syndromic CHD which is higher than previously 
reported.  We initially expected a prevalence of syndromic CHD which was lower than 
previously reported among all individuals of all ages with CHD, because neurologic features 
may not be apparent and dysmorphic features may be subtle during the neonatal period.  Our 
results could indicate that many neonates with CHD have some additional, but sometimes subtle, 
syndromic features.  In this case, fewer patients may have truly isolated CHD than suggested by 
previous studies.  This may, in large part, be attributed to our study population of neonates which 
 77 
 
are likely to have severe cases of CHD due to admission to a large tertiary care center.  Our 
results could also be attributed to our broad criteria for categorizing apparently syndromic CHD.  
The criteria for the assessment of apparently syndromic CHD may be made more stringent in the 
continuation of this study to determine if the prevalence remains as high.  By reassessing the 
detection rate of CNVs in a larger sample size with more stringent criteria for syndromic CHD, 
we will also be able to determine if the detection rate remains significantly greater among 
patients with apparently syndromic CHD.  This may help to define characteristics of the 
population among which array CGH will have the greatest detection of pathogenic CNVs.                                     
4.1.6 Conclusion   
The results of our study support the conclusion that array CGH has significant clinical 
efficacy as a first-tier test among neonates with CHD.  Our data to this point suggests that array 
CGH increases detection rate by approximately 20% in this population, compared to classical 
cytogenetic analysis alone.   However, interpretation of the significance of results can be 
challenging, and the majority of CNVs detected in our study had unclear clinical significance.  
Further analysis is warranted in a larger sample size to clarify the detection rate of CNVs with 
clinical significance versus uncertain clinical significance.  As array CGH continues to be 
utilized among neonates with CHD, the identification of additional genes associated with CHD 
and the expansion of databases of pathogenic CNVs will facilitate result interpretation.  Array 
CGH does not always provide a clear answer regarding causality and recurrence risk for CHD, 
and additional testing for monogenic disorders may be required in cases which are suggestive of 
a particular syndrome.  Therefore, the collaboration between Cardiology and Medical Genetics is 
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critical in cases with CNVs of uncertain clinical significance.  Despite these challenges, array 
CGH does have the potential to detect pathogenic CNVs that are undetectable by standard 
methods of chromosome analysis.  In these cases, the information provided by array CGH to 
patients, physicians, and families is invaluable.                                                                                                           
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APPENDIX A:  CASE REPORTS 
COPY NUMBER VARIANTS DETECTED BY ARRAY CGH 
4.1.7 Case 110 
Case 110 is a male with mixed ethnicity (African American, Italian, and Greek), born at 
39 weeks of age.  This patient was diagnosed with Double Outlet Right Ventricle, Tetralogy of 
Fallot type and severe PS.  He was small for gestational age, with growth parameters at age 4 
weeks of 7% for weight, 1% for length, and 2% for head circumference.  No obvious deformities 
were noted by cardiology.  On an exam by a geneticist, minimal dysmorphology was noted, 
including ears which were low-set and posteriorly rotated as well as excess skin on the neck 
related to a possible cystic hygroma.  Phenotypic features noted to be normal variation included 
round facies and inverted nipples; the remainder of the physical exam was normal.                                       
Classical cytogenetic analysis revealed a large deletion of approximately 7.7 Mb in size 
at chromosome 3p22.2 to p23; array CGH confirmed this deletion and defined the breakpoints 
(see Table 3).  Factors considered in the assessment of clinical significance included:  
• Previous Reports:  Two deletion 3p syndromes have been reported: deletion 3p syndrome 
with breakpoints between 3p24 and 3p25 (which would not overlap this region) and 
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proximal deletion 3p syndrome with various breakpoints between 3p11 and 3p21.2 (a 
much larger deletion which overlaps this region).  There is one case report of an 
interstitial deletion which overlaps with the region of interest, spanning from 3p22.2 to 
3p24.2.  Features noted in this case included global developmental delay, mild 
dysmorphic features, and short stature (61).        
• Gene Content:  Thirty-five OMIM genes are included in the deleted region, including 
seven genes with known disease associations: MLH1, ACVR2B, GPD1L, SCN5A, GLB1, 
CRTAP, and MYD88 (56).         
o Heterozygous mutations in ACVR2B are associated with Visceral Heterotaxy-
4, resulting in the abnormal placement of abdominal organs; this syndrome 
has been associated with various types of CHD (60).         
o Heterozygous mutations in GPD1L and SCN5A are associated with multiple 
syndromes involving the sodium channel of the heart.  These disorders include 
Familial Atrial Fibrillation 10, Brugada Syndrome I and II, Dilated 
Cardiomyopathy IE, Heart block (nonprogressive and progressive type IA), 
Long QT syndrome 3, Familial ventricular fibrillation 1.  Each of these 
disorders have reduced penetrance (60).  To our knowledge, the effect of 
whole gene deletions of GPD1L or SCN5A has not been reported.                      
o Heterozygous mutations in the tumor suppressor gene MLH1 cause Hereditary 
Non-Polyposis Colorectal Cancer syndrome (Lynch syndrome).  Therefore, 
this patient was also given a diagnosis of Lynch syndrome, which causes an 
increased risk for adult-onset cancers including colorectal, uterine, ovarian, 
stomach, kidney, urinary tract, small bowel, brain/ central nervous system, 
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and skin cancers.  These malignancies are thought to develop as a result of 
one germline mutation and one somatic mutation in MLH1.  This was an 
incidental finding, not related to this patient’s CHD.                    
o Several genes in the region of interest are associated with autosomal recessive 
conditions.  Homozygous mutations in SCN5A are associated with Sick Sinus 
Syndrome 1 and susceptibility to SIDS (autosomal recessive or 
multifactorial), homozygous mutations in GLB1 cause GMI-gangliosidosis 
and Mucopolysaccharidosis Type IVB, homozygous mutations in CRTAP 
cause Osteogenesis Imperfecta Type IIB and VII, and homozygous mutations 
in MYD88 are associated with recurrent pyogenic bacterial infections (60).  
Case 110 is an asymptomatic carrier of each of these conditions, and would 
not be affected except in the case of a mutation in the remaining allele.          
• Parental studies:  Parental studies were offered because of the implications of Lynch 
syndrome and other syndromes involving the sodium channel of the heart, as well as 
to provide reproductive risk information.  The parental studies have not yet been 
completed, therefore it is uncertain if this deletion is de novo or inherited.            
In summary, this patient has CHD and minimal dysmorphology with a clinically 
significant deletion detected by array CGH.   This is a large deletion with more than twenty 
genes in the deleted region (a threshold proposed by Thienpont et al) (12).  Because several of 
these genes have been associated with defects in cardiac structure and function, this deletion is 
likely causal for the patient’s CHD.  Of note, this patient was the only patient in our study with a 
CNV large enough to be detected by both classical cytogenetic analysis and array CGH.         
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4.1.8 Case 118 
Case 118 is a male of unspecified race, born prematurely at 33 weeks gestation.  He was 
diagnosed with a complex CHD including D-TGA with VSD, AS, COA, and DORV.  In 
addition, an EKG showed left ventricular hypertrophy but a normal sinus rhythm.  This patient 
had various extracardiac abnormalities, including a right inguinal hernia, pulmonary 
insufficiency, right optic nerve hypoplasia, nystagmus, tremors, and feeding intolerance.  He 
received a Medical Genetics consult due to concern for dysmorphic features.  Features noted on 
exam included a sloping and hairy forehead, puffy eyes, very high palate, hypertrophic gums, 
slight redundant folds of the neck, some joint restriction, fine tremor and hypertonia.                    
There were also exposures during pregnancy that included benzoate, tobacco, and a history of 
HSV and Chlamydia infection.  A brain MRI identified periventricular leukomalacia of the left 
anterior periventricular white matter, a thin corpus callosum, and delayed myelination, with no 
evidence of hemorrhage.  An ultrasound of the head revealed small bilateral subependymal 
hemorrhages and a tiny choroid plexus cyst.  In addition, a renal ultrasound revealed mild 
bilateral pelviectasis.                
This patient had a normal karyotype by standard cytogenetics, but a duplication in the 
region of 16q21 of approximately 683 kb was detected by array CGH.  Factors considered in the 
assessment of causality of this CNV included:               
• Previous reports:  There are no published case reports of similar duplications, and this 
duplication is not listed in a database of normal variants (55, 57).              
• Gene Content:  There are a total of seven genes in this region; two are listed in OMIM 
and both are protein-coding (56).  CNOT1 encodes a subunit of the CCR4-NOT 
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transcription complex, which is a global regulator of RNA polymerase II transcription 
(62).  GOT2 encodes mitochondrial glutamate oxaloacetate transaminase, which is an 
aminotransferase localized to the mitochondria.  This protein may be involved in the 
activity of tyrosine aminotransferase (TAT) in the mitochondria (63).  The potential 
dosage effect of these protein products is unclear; neither genes have been associated 
with monogenic diseases or with cardiac development (60).                         
• Parental studies:  The duplication was confirmed by FISH to be maternally inherited.  
This decreases the likelihood that this CNV is causal for the patient’s phenotype, as his 
mother was not found to have similar clinical features, but does not rule out causality due 
to the possibility of reduced penetrance and variable expressivity.  It was recommended 
that the patient’s mother receive a baseline Cardiology evaluation in the case that this 
duplication is associated with the patient’s CHD.                       
In summary, this patient has a relatively small duplication with unclear clinical 
significance detected by array CGH; is likely to be benign as the two OMIM genes in the region 
do not have a known dosage effect and the CNV is inherited.  However, this patient has 
apparently syndromic CHD.  The conclusion of a Medical Genetics evaluation was that this 
duplication does not explain the patient’s heart defect and other clinical findings.  Testing for 
other single gene disorders was initiated with MLL2 for Kabuki syndrome which was negative.  
A Noonan syndrome panel, urine organic acids for inborn errors of metabolism, and a sterol 
panel for Smith-Lemli-Opitz syndrome were recommended but not yet completed.  Other 
differentials which may be explored in the future include CHARGE syndrome, DiGeorge 
syndrome II, and connective tissue disorders.                                       
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4.1.9 Case 119      
Case 119 is Caucasian male born full-term at 39 weeks gestation and diagnosed with 
congenital complete heart block and two small ASDs.  Growth percentiles at 17 hours of life 
were 20% for weight, 5% for length, and 13% for head circumference.  Features noted on an 
exam for dysmorphology included hypotelorism, puffy eyes, nails which were extremely thin on 
the hands and hypoplastic and thin on the feet, edema, jaundice, a dystrophic scar, short neck 
with redundant skin, ears described as punched out helix and angulated, an extra crease on the 
hands, and a deep sacral dimple.  Pertinent environmental factors in this case included possible 
enteric virus, sepsis, and maternal lupus.  A head ultrasound was normal, while a renal 
ultrasound revealed mild pelviectasis of the left kidney.                            
Array CGH revealed a deletion of 3p26.3, spanning at least 295 kb.  Factors considered 
in the assessment of clinical significance of this CNV included:  
• Previous Reports:  There are no published case reports of similar deletions.  This deletion 
has not been reported in a database of normal variants (55, 57).                     
• Gene Content:  One gene, CNTN6, also known as NB-3, is located within the deleted 
region (56).  This gene encodes a neural adhesion molecule in the contactin subgroup of 
the immunoglobulin superfamily.  Contactins are expressed exclusively in the nervous 
system, and are essential to formation and maintenance of synaptic connections in the 
adult brain, with highest expression in the cerebellum (64).  Dosage sensitivity of CNTN6 
is unclear and it has not been associated with any monogenic diseases.       
• Parental studies have not yet been completed.      
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In summary, this patient has a deletion with unclear clinical significance; it is relatively 
small and includes only one gene which is not known to be associated with cardiac development 
or monogenic diseases.  Without any further information, it appears to be unlikely to be causal 
for the patient’s CHD.  This patient has apparently syndromic CHD based on the criteria used for 
this study, but did not receive a comprehensive evaluation by Medical Genetics to determine if 
additional genetic testing is warranted.         
4.1.10 Case 121     
Case 121 is a full-term Caucasian female born at 39 weeks gestation and diagnosed with 
hypoplastic left heart syndrome, including mitral atresia, hypoplastic left ventricle, aortic atresia, 
hypoplastic ascending aorta.  This patient was small for gestational age with growth percentiles 
at 1 day of life of 13% for weight, <1% for length, and 15% for head circumference.  A basic 
dysmorphology exam was completed per standard of care, but this patient did not receive a 
comprehensive Medical Genetics evaluation.  Phenotypic features noted on exam included left 
hip dysplasia, gross lower extremity and labial edema, ankyloglossia, borderline low set ears, 
possible anteriorly placed anus, prominent chest, hypotonia, and a premature for age appearance.    
This patient was found to have a duplication in the region of 1q21.1, spanning at least 
1.19 Mb.  Factors considered in the assessment of clinical significance included the following:            
• Previous reports:  Duplications in this region are associated with chromosome 1q21.1 
duplication syndrome, which has been well-defined in the literature.  This region is rich 
in complex low-copy repeat segments, and CNVs in the region are frequently inherited 
and have incomplete penetrance and variable expressivity.  Associated features include 
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macrocephaly, frontal bossing, hypertelorism, hypoplasia of the corpus callosum and 
cerebellar vermis, seizures, developmental delay and mental retardation, learning 
disabilities, as well as psychiatric manifestations such as autism and schizophrenia, and 
various dysmorphic features with no clear pattern (58, 65, 66).  Macrocephaly has been 
reported in 50% of cases of 1q21.1 duplication syndrome, and is thought to be caused by 
a dosage effect of the HYDIN gene located in this region (65).  Patient 121 had a head 
circumference percentile of 15% at 24 hours, so she did not have macrocephaly at the 
time of assessment.  Deletions within the 1q21.1 region have been associated with CHD, 
particularly anomalies of the aortic arch (67).  Case reports of CHD associated with 
duplications of this region also exist: among 24 patients with a 1q21.1 duplication, 
Brunetti-Pierri et al. reported one case with a complex CHD.  Of note, they also reported 
one case with congenital hip dysplasia, similar to our patient (58).                
• Gene content:  This region contains 9 OMIM genes, all of which are protein-coding (56).  
Two genes are associated with monogenic diseases caused by heterozygous mutations: 
GJA5 encodes a connexin protein which is involved in gap junctions for ion and small 
molecule transport between cells; heterozygous mutations are associated with Familial 
Atrial Fibrillation-11 (68).  GJA8 encodes a connexin protein which is involved in gap 
junctions connecting fiber cells of the lens; heterozygous mutations are associated with 
cataract and microcornea syndromes (69).  Because Case 121 has a duplication of this 
region, not a deletion, these syndromes are not likely to be clinically relevant.            
• Parental studies were not completed.            
Because this duplication is part of a well-defined syndrome, it is likely that the 
duplication accounts for this patient’s syndromic features.  This also provides important 
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information regarding the monitoring of this patient for any neurologic features.  Because CHD 
has been previously associated with a 1q21.1 duplication, it is likely that this patient’s CHD is 
related to the duplication.         
4.1.11 Case 127 
Case 127 is a Caucasian female born full-term at 39 and 1/7 weeks gestation.  She 
presented with acute enterovirus myocarditis and severe cardiomyopathy.  She was originally 
suspected to have COA, but this was ruled out; the only structural heart defect remaining was a 
bidirectional PFO.  Growth percentiles at 6 days of life were 67% for weight, 39% for length, 
and 36% for head circumference.  Subtle dysmorphic features were noted on a limited exam, 
including a microcephalic and plagiocephalic head shape, slight mid facial hypoplasia, deep-set 
and upslanted eyes, low-set posterior hairline, short neck, shield chest, and deep sacral cleft.  An 
EKG revealed several abnormalities, including a sinus rhythm with occasional premature 
ventricular complexes, biatrial enlargement, a northwest axis, and a possible lateral infarct.  A 
head ultrasound was normal, while a renal ultrasound revealed a small amount of free perihepatic 
and pelvic fluid but was normal overall.  Of note, this patient’s mother had gestational diabetes 
treated with insulin during the pregnancy and was also treated for hypothyroidism.                
Classical cytogenetic analysis was normal but array CGH revealed a deletion of 358 kb in 
size in the region of chromosome 2q21.3.  Factors considered in the assessment of clinical 
significance included:               
• Previous reports:  There are no case reports of similar deletions, nor is this deletion found 
in a database of normal variants (55, 57).                    
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• Gene Content:  This region contains two OMIM genes, CCNT2 and RAB3GAP1, as well 
as three other genes (56).  CCNT2 encodes a cyclin protein which forms a complex with 
CDK9 which may moderate RNA polymerase II activity (70). RAB3GAP1 encodes the 
catalytic subunit of the RAB3 GTPase-activating protein; this protein inactivates RAB3-
GTP to regulate synaptic transmission and plasticity (71, 72).  Overall, members of the 
RAB3 family are involved in regulating the exocytosis of neurotransmitters and 
hormones.  Homozygous mutations in RAB3GAP1 cause Warburg micro syndrome 1.  
This syndrome is associated with ocular, neurodevelopmental, and metabolic 
manifestations, specifically hypothalamic hypogenitalism (73).  Case 127 would be an 
asymptomatic carrier for this condition, except in the case of a mutation in the remaining 
allele.  Dosage effects of the genes in this region of copy number variation are unclear, 
and neither OMIM gene is known to be associated with monogenic diseases or cardiac 
development.              
• Parental testing has not yet been completed.        
In summary, this patient had severe cardiomyopathy and PFO as well as subtle 
dysmorphic features.  The deletion detected by array CGH is relatively small and does not 
include any genes implicated in cardiac development.  Without further information from 
published case reports or parental studies, it is unclear whether the deletion detected by array 
CGH contributed to this patient’s CHD and cardiomyopathy.  This patient did receive an 
inpatient Genetics evaluation; an ophthalmology evaluation was recommended to rule out 
Warburg syndrome, but no additional genetic testing has been completed to date.                       
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4.1.12 Case 128 
Case 128 is a Caucasian female born at 38 and 6/7 weeks gestation.  Growth percentiles 
at 15 hours of life were 4% for weight, 12% for length, and 0% for head circumference, 
consistent with microcephaly.  This patient was diagnosed with TOF, including pulmonary 
atresia and VSD.  Abnormal features noted on an exam for dysmorphology included a V-shaped 
high cleft palate, low-set and posteriorly rotated ears, and a narrow and possibly beaked nose.  
On examination, other features which could be normal variation included mild plagiocephaly, 
bitemporal narrowing, low posterior hairline, normal eyes with mild hypertelorism, 
ankyloglossia, and a sacral dimple.  Other extracardiac features included a swallowing disorder 
and post-surgical thrombosis.  Testing confirmed that this patient carries a heterozygous Factor 
V Leiden mutation which could related to the thrombosis.  A head ultrasound was normal, and a 
renal ultrasound revealed minimal left caliectasis but was otherwise normal.  Classical 
cytogenetic analysis was normal but array CGH revealed a pathogenic deletion spanning 535 kb 
at chromosome 16p11.2.  Factors considered in assessing clinical significance included:                                      
• Previous Reports: This deletion is known as 16p11.2 microdeletion syndrome, a 
contiguous gene syndrome associated with deletions of approximately 550 kb at this 
locus.  This syndrome is associated with up to 1% of cases of autism spectrum disorder.  
This syndrome is associated with a variety of other clinical features, including DD/ID, 
severe early-onset obesity, dysmorphic facial features, congenital anomalies, and possibly 
other primary psychiatric disorders (74-76).  There is also a case report of two 
monozygotic twins with an aortic valve abnormality, seizure disorder, and mild ID 
associated with a 16p11.2 microdeletion (59).  This syndrome is noted to have variable 
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expressivity, incomplete penetrance and it can be inherited from either an affected or 
asymptomatic parent.  Males appear to be more likely to be affected with autism than 
females, even among individuals with this syndrome.  Duplications of this region are also 
associated with autism, but are more likely to have reduced penetrance and less likely to 
be associated with dysmorphism (74).              
• Gene Content: This region contains 18 OMIM genes, including SPN, QPRT, MAZ, 
C16orf53, MVP, CDIPT, KCTD13, CORO1A, BOLA2, SULT1A3, TAOK2, HIRIP3, 
DOC2A, ALDOA, PPP4C, TBX6, YPEL3, and MAPK3 (56).  All are protein-coding, but 
only one is associated with a monogenic disease.  Homozygous mutations in ALDOA, 
which encodes the protein Aldoase A, Fructose-Bisphosphate, cause glycogen storage 
disease type XII (77).  Due to the deletion of this region, Case 128 would be an 
asymptomatic carrier for this condition, except in the rare case of a mutation in the other 
allele.      
• Parental studies have not yet been completed.  
In summary, this patient has an apparently syndromic congenital heart defect.  She has a 
clinically significant deletion of 16p11.2, associated with a well-defined microdeletion 
syndrome.  This syndrome has been associated with multiple congenital anomalies and 
neurologic manifestations, and therefore likely explains this patient’s phenotypic features.  Based 
on previous case reports of CHD associated with 16p11.2 deletions, this deletion is likely causal 
for the patient’s CHD.  This patient was evaluated by Medical Genetics, and it was not felt that 
additional testing was necessary at this time.                                                         
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4.1.13 Case 132     
 Patient 132 is a female of unspecified race, born at 39 and 3/7 weeks gestation.  This 
patient was small for gestational age, with growth percentiles at 8 hours of life of 18% for 
weight, <1% for length, and 1% for head circumference.  This patient was diagnosed with a 
complex CHD, with a functional single ventricle consisting of a double inlet left ventricle and 
hypoplastic right ventricle, as well as PS and VSD.  Features noted on a dysmorphology exam 
included microcephaly, simple ears, sacral dimple, deep, upslanted eyes, broad-tipped nose, short 
neck, possibly abnormal nails, weak cry, bicycling movements, and multiple hemangiomas.  
These capillary malformations appeared as pink macules on the abdomen, back, groin, and 
genital/ buttock region.  Head and renal ultrasounds were normal.  Nonspecific debris in the 
bladder and echogenic renal cortices was noted on the abdominal ultrasound; however this was 
noted to be possibly normal variation.  Other extracardiac abnormalities included left-sided 
hemihypertrophy and a portal vein thrombus.                   
This patient had a normal karyotype by classical cytogenetic analysis, but a 346 kb 
deletion at chromosome 22q12.3 was detected by array CGH.  Factors considered in the 
assessment of pathogenicity included the following:           
• Previous Reports:  Similar deletions have not been previously reported, and this CNV has 
not been reported in a database of healthy individuals (55, 57).            
• Gene Content:  This deletion contains a portion of the gene LARGE (56) , which is a 
member of the N-acetylglucosaminyltransferase family.  LARGE recognition and 
glycosylation is essential to the expression of functional alpha-dystroglycan which 
prevents muscle degradation (78, 79).  Homozygous mutations or deletions of this gene 
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have been associated with Walker-Warburg syndrome, also known as muscular 
dystrophy-dystroglycanopathy types A and B.  Type A includes muscular dystrophy with 
brain anomalies and eye anomalies, while type B includes muscular dystrophy and 
mental retardation; onset ranges from prenatal to six months of life (80, 81).  Patient 132 
would be an asymptomatic carrier for these syndromes unless she carried a mutation in 
the remaining copy of LARGE.  An elevated CPK level would be expected in patients 
with these syndromes; this patient’s CPK was 37 (reference range of 42-470).       
• Parental studies:  This deletion was determined to be paternal in origin by FISH analysis.   
In summary, Patient 132 has an apparently syndromic CHD, with various extracardiac 
abnormalities and dysmorphic features.  The deletion detected by array CGH has unclear clinical 
significance.  It is less likely to be causal for this patient’s phenotype because it was also 
detected in the patient’s father, but this does not rule out the possibility of pathogenicity due to 
variable expressivity.  This patient did receive a comprehensive Medical Genetics evaluation.  
Due to this patient’s hemihypertrophy and capillary malformations, Klippel Tranauny Weber 
syndrome was considered as a differential diagnosis.       
4.1.14 Case 140 
 Patient 140 is a Caucasian female born at 38 and 3/7 weeks gestation.  This patient was 
small for gestational age; growth percentiles at 30 hours of life were <1% for weight, length, and 
head circumference.  This patient was diagnosed with an unbalanced complete AVSD, with a 
dominant right ventricle, small left ventricle, and transverse arch hypoplasia (causing right 
ventricular outflow tract obstruction).  This CHD was apparently isolated:  no dysmorphic 
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features were noted on exam and the patient was considered non-dysmorphic in appearance both 
by Cardiology and Genetics evaluations.  Of note, this patient did have sclera erythema which 
was attributed to labor, as well as symptoms of neonatal narcotic withdrawal from a maternal 
history of hepatitis C and heroin use, smoking and methadone dependency.                                   
This patient had a normal karyotype by classical cytogenetic analysis but a deletion of 
1.36 Mb was detected by array CGH.  Factors considered in the assessment of clinical 
significance included the following:           
• Previous reports:  Similar deletions have not been reported in the literature or in a 
database of healthy controls (55, 57).       
• Gene content:  The deleted region contains the 5’ region of SUCLG2 and is just upstream 
of TMF2, both of which are OMIM genes (55).  SUCLG2 encodes the beta subunit of 
Succinate-CoA ligase; this enzyme is localized to the mitochondria and is involved in the 
tricarboxylic acid cycle and carbohydrate metabolism (82).  TMF2, or TATA element 
modulatory factor 1, has several functions.  It mediates the degradation of STAT3 
(involved in the cell response to interleukins), possibly acts as a coactivator of the 
androgen receptor, and binds the TATA element of HIV-1 to inhibit transcription (82).  
The deleted region also contains two other protein-coding genes not listed in OMIM, 
FAM19A1 and FAM19A4, which may be involved in regulation of immune and nervous 
cells in the brain (83).  None of these genes have been associated with monogenic 
diseases, but because of their roles in metabolism and transcriptional regulation, a dosage 
effect is possible.                      
• Parental studies: Parental studies have not yet been completed.  
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This deletion has unclear clinical significance, as there is a paucity of information from 
previous reports or parental studies to assess pathogenicity.  In addition, it is possible that 
maternal environmental exposures contributed to this patient’s heart defect.  Because this patient 
had apparently isolated CHD, she did not receive a full Medical Genetics evaluation and no 
additional testing for single gene disorders was completed.             
4.1.15 Case 141  
Patient 141 is a male with unknown race born at 39 weeks gestation.  Growth percentiles 
at 21 hours were 2.91% for weight, 25.26% for length, and 5.76% for head circumference; this 
patient had symmetric IUGR.  This patient was diagnosed with hypoplastic left heart syndrome 
(HLHS), including mitral stenosis, aortic atresia, and a small secundum ASD.  Several abnormal 
features were noted on a dysmorphology examination, including deep-set and puffy eyes, down-
slanting palpebral fissures, a loose, webbed and short neck, a deep sacral dimple, right club foot, 
and loose skin with gross edema.  Other phenotypic features which may be normal variation 
included a frontal bossing, low set and posteriorly rotated ears with an over-folded right ear and 
a Darwinian tubercle of the left ear, a broad nasal bridge, hypoplastic nipples, slight shield chest 
appearance, 5th left finger clinodactyly, hypoplastic toenails, and a decreased suck reflex.  
Additional extracardiac features included edema, presumed sepsis, and a diagnosis of congenital 
hypothyroidism.  A head ultrasound was normal and a renal ultrasound revealed minimal left 
upper pole caliectasis but was otherwise normal.  Due to the deep sacral dimple, a spine 
ultrasound was ordered to rule out a tethered cord, which was normal.  This patient was noted to 
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be non-dysmorphic by Cardiology but was considered to have an overall dysmorphic appearance 
by Medical Genetics.                                  
This patient had a normal karyotype by classical cytogenetic analysis, but array CGH 
detected a duplication in the region of chromosome 20p11.21 spanning approximately 398 kb 
(breakpoints 25,016,046- 25,414,542).  Factors considered in the assessment of clinical 
significance included the following:                
• Previous Reports:  Similar duplications have not been reported in a database of healthy 
individuals.  One report of an individual with a similar duplication (breakpoints 
25,096,493- 25,467,359) inherited from a normal parent was noted to have dysmorphic 
features, high palate, joint laxity, tall stature, DD/MR, voice abnormalities and behavioral 
problems (55, 57).                   
• Gene Content:  The duplicated region contains 5 OMIM genes, including ENTPD6, 
PYGB, ABHD12, GINS1, and NINL (56).  ENTPD6 encodes an enzyme which may be 
involved in the glycosylation reactions in the Golgi apparatus and the catabolism of 
extracellular nucleotides; it is expressed mainly in the heart.  PYGB encodes a glycogen 
phosphorylase which is involved in carbohydrate metabolism.  ABHD12 encodes a lipase 
which is involved in synaptic plasticity and neuroinflammation (82).  Homozygous 
mutations in this gene cause a syndrome involving polyneuropathy, hearing loss, ataxia, 
retinitis pigmentosa, and cataract (PHARC) (84); however, this patient carries a 
duplication of the ABHD12 gene.  GINS1 encodes a subunit of the GINS complex which 
is involved in DNA replication.  NINL encodes a protein which is involved in 
microtubule organization of interphase cells (82).                             
• Parental studies have not been completed.      
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In summary, this patient had apparently syndromic CHD and a relatively small 
duplication with unclear clinical significance.  There was one report of a similar duplication 
which was pathogenic, but not associated with CHD.  It is unclear whether this CNV contributed 
to this patient’s CHD.  This patient received an inpatient genetics consult prior to receiving 
results from array CGH.  Because of the constellation of dysmorphic features and extracardiac 
features in this patient, testing for Noonan syndrome was ordered and was pending at the time of 
this report.          
4.1.16 Case 102   
 Patient 102 is a female of unspecified race, born at 39 weeks gestational age.  This patient 
was small for gestational age, with growth percentiles at 10 days of life of 23% for weight and 
<1% for length and head circumference.  This patient was diagnosed with Tetralogy of Fallot.  
Phenotypic features noted on a Medical Genetics examination included a large anterior 
fontanelle, bell-shaped chest, prominent calcaneous (heel bone) of the feet bilaterally, a crease in 
the right arm similar to Madelung’s deformity, pauses in breathing, and somewhat hypoplastic 
nails.  Extracardiac features included subglottic stenosis requiring a tracheostomy and a humerus 
fracture.  However, bones and soft tissue were otherwise normal, as were a brain MRI, head 
ultrasound and renal ultrasound.  An abdominal x-ray showed trace ascites.                        
Classical cytogenetic analysis revealed a balanced translocation which was paternally 
inherited; the karyotype was 46,XX,t(6:10)(p21.2;p15).  Normal array CGH results confirmed 
the balanced nature of this translocation at a resolution of 135 kb.  This patient did receive a 
complete Genetics evaluation.  Because this patient had multiple congenital anomalies, there was 
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strong suspicion for a genetic syndrome.  Because the translocation was confirmed to be 
balanced, it is not likely to be causal for this patient’s phenotype unless imprinted genes in the 
region are affected.  In addition, the patient’s father, who also carries the translocation, is 
unaffected.  Of note, the DiGeorge syndrome II region is located at 10p13-14 and the breakpoint 
for this patient’s translocation is at 10p15; the significance of this proximity to the DiGeorge 
region is unclear because there is no apparent loss or gain of genetic material.               
To this point, no additional genetic testing has been performed, but the suggested 
differentials include a microdeletion syndrome not detected by this array CGH platform, single 
gene disorders such as Noonan syndrome, Kabuki syndrome, Alagille syndrome, or a single gene 
mutation in JAGGED1 or NKX2.5.  The patient will be monitored for features which would be 
suggestive of any specific syndromes and further testing may be performed in the future.                            
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